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ABSTRACT  
 
Myotonic Dystrophy type 1 (DM1) is a multisystem progressive disorder with high 
heterogeneity. Novel emerging therapies require assessment tools that can 
effectively assess the effects of an intervention. The Outcome Measures in 5 
Myotonic Dystrophy (OMMYD) Consortium has proposed a battery of functional 
outcome measures (FOM) identified as relevant for clinical trials in DM1. 
However, due to the variable nature of the disease and a scarcity of resources, 
there is a lack of systematic research that properly explores the use of these 
FOM. The current study examined three of these FOM and one extra related to 10 
patients’ daily life performance. These are: (1) the ten-meters walk test; (2) the 
ten-meters walk/run test; (3) the 30-seconds sit and stand test; and, (4) a tri-axial 
accelerometer. By exploring the reliability, validity and responsiveness of these 
outcomes, we aimed to establish reference values and standard methodologies 
that could serve as guidance for clinical trials in DM1. A cohort of DM1 adults 15 
screened for the two largest-to-date trials in DM1 (OPTIMSITIC and PHENO-
DM1) were examined in relation to a set of pre-specified assessments and 
disease-burden scores. The results of this thesis supply disease-specific 
evidence of their validity, reliability and feasibility. The FOM, have shown to be 
psychometrically robust measures of functionality in DM1 and to be feasible for 20 
clinical trials; they can provide a picture of patients’ muscle strength and 
perceived mobility and participation in life. The accelerometer can objectively 
quantify joints accelerations when walking at different speeds and summarise a 
DM1 patient’s habitual physical activity. The final choice of an outcome measure 
for a clinical trial in DM1 should be guided by disease domain that an intervention 25 
is likely to impact on; but, a disease-specific study like this one will reduce the 
burden of protocol design whilst providing evidence supporting the decision-
making process. 
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CHAPTER 1. BACKGROUND 
 
1.1. INTRODUCTION 
 
Myotonic Dystrophy Type 1 (DM1; Steinert’s Disease) is a rare, autosomal-5 
dominant neuromuscular disorder, characterized by progressive muscle 
weakness, myotonia and multisystem involvement. It is the second most 
common form of inherited muscular dystrophy and the most common amongst 
adults with a prevalence of 1:8,000 to 1:10,000 in the general population (1-3). 
In the northern region of England, patients with DM1 comprise 28.6% of the 10 
clinic population registered at the John Walton Muscular Dystrophy Research 
Centre(4).   
 
Due to the nature of the disease and its heterogeneous phenotype, 
understanding its molecular and clinical complexity has been a challenging task. 15 
Still, potential treatments have emerged in the last decade, thus requiring the 
establishment of the best methods to measure disease progression and 
therapeutic impact. The rationale for this thesis has been to explore potential 
outcome measures and biomarkers suitable for implementation in DM1 clinical 
trials. 20 
 
1.2. MYOTONIC DYSTROPHY TYPE 1 
 
DM1 is caused by a repeat expansion (≥50 CTGn) in the 3’ untranslated region 
of the DMPK (myotonic dystrophy protein kinase) gene located at chromosome 25 
19q13.3 (1, 5). Although the detailed molecular understanding of this disorder is 
not yet fully understood, it is known that the nuclear accumulation of the 
resulting mutant CUG - RNA segments that remain un-translated inside the 
nucleus are the major factors resulting in this disorder (5). This mutation itself 
largely determines disease severity, progression and age of onset; and, the 30 
instability of this expansion results in a phenomenon of anticipation, increasing 
severity and a decreasing age of onset by generations (6, 7).  
 
2 
 
The main factor for this pathology is a miss-regulation of two RNA-binding 
protein families: (1) the loss-of-function of the MBNL proteins, which normally 
are highly expressed in the cardiac muscle, skeletal muscle and brain (8); and, 
(2) the overexpression of the muscle specific CUG binding protein (CUGBP1) 
(9). These two proteins regulate the developmental splicing process, and even 5 
though >80% of the alterations may be explained particularly by the loss-of-
function of MBNL1, it seems that it is the ratio between these two that 
determines the pathogenic features (10). The following are relevant examples of 
proteins affected by this disrupted translational process in DM1: [1] the CLCN1 
(muscle-specific chloride channel), a protein involved in the active contraction, 10 
the aberrant version of CLCN1 in DM1 has been identified as the source of the 
myotonia (11); [2] the BIN1 (bridging integrator) protein, an organizer of the T-
tubule muscular network, when mutated the skeletal muscle presents with 
reduced strength(12); and, [3] the PKM (pyruvate kinase), an essential enzyme 
of the glycolysis process, when the embryonic isoform of PKM prevails in DM1 it 15 
results in high levels of muscle energy expenditure and muscle fatigue (13). 
 
DM1 is a multi-systemic disorder with a high heterogeneity in cognitive, physical 
and functional levels among patients. The most affected organs involve post-
mitotic tissues, such as skeletal muscle, cardiac conduction system and the 20 
central nervous system (3, 14). DM1 is typically characterized by progressive 
muscle wasting and weakness combined with the ‘myotonia’ phenomenon. This 
associated muscle weakness is a slow but persistent process that finally limits 
functional mobility (15).  
 25 
With a highly variable clinical manifestations and age of onset, DM1 can be 
classified into three somewhat overlapping phenotypes but with different speeds 
of disease progression and severity (2, 3, 16):  
a) The congenital phenotype, that is almost exclusively maternally 
inherited, is considered the most severe form and is characterized by 30 
symptoms at birth or in the postnatal period such as generalized muscle 
weakness and hypotonia, talipes, mental retardation, feeding problems 
and severe cardiorespiratory complications; the latter being the main 
cause of death. 
3 
 
b) The classic phenotype or adult onset type, presents with a relatively 
slow progressive muscle weakness, this progresses from distal to 
proximal, starting in the distal limbs (finger flexors, and wrist and ankle 
extensors), neck extensors and facial muscles. Patients have been 
historically portrayed with the typical myotonic-face characterized by 5 
bilateral ptosis and wasting of the jaw and temporal musculature. 
Myotonia is the recognized hallmark of the disorder when compared to 
other muscular dystrophies and is commonly observed in the hand after 
a voluntary handshake or elicited grip.  
These patients also present with premature cataracts, nasal speech, 10 
cardiac conduction abnormalities, gastrointestinal tract involvement, 
fatigue, excessive daytime sleepiness (EDS) and cognitive impairment.  
Cardiac manifestations commonly include myocardial fibrosis and 
conduction system abnormalities in 65%-90% of patients having 
conduction abnormalities with a high risk for sudden cardiac death (17). 15 
c) The late onset form can sometimes be considered as mild or 
asymptomatic as it is not usually diagnosed until pedigree screening or 
specific clinical assessments most commonly detect it. Typical, non-
specific manifestations include cataracts and mild myotonia. It is 
associated with a normal life span. 20 
 
Collectively these clinical manifestations lead to physical impairment and 
restricted social participation impacting considerably on the health-related 
quality of life indices of patients with DM1 and their families (18). Unfortunately, 
there is not yet a proven treatment that will relieve disease impairments, reduce 25 
limitations and optimise participation altogether. Measuring the impact of an 
intervention at all these levels and identifying possible cut-off points that impact 
on the patient’s quality-of-life allows potential therapeutics to act based on 
relevant results.  
 30 
1.3. FUNCTIONALITY AND DISABILITY IN DM1 
 
In 2001 the World Health Organisation (WHO) established a new way for 
measuring health and disability providing a classification system that will 
standardize the language to describe an individual’s health status not only 35 
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based on their own disease-related characteristics but also related to each 
individual’s environment (19). This classification system is the International 
Classification of Functioning, Disability and Health (ICF) and is structured 
around three broad components: Body functions and structure (impairments at 
the body structure or functioning level); activities (experienced limitations at the 5 
individual’s activity level); and participation (level of involvement as a member of 
society); these interact between each other based on the personal and 
environmental factors that affect each individual (Figure 1). One of the aims of 
the ICF is to reach an understanding of health and health-related outcomes in a 
common language that allows comparison (19). 10 
 
 
Furthermore, when describing someone’s activity and participation levels, these 
can be described as either capacity or performance (19). The latter refers to 
what someone accomplishes in his or her real-life and current environment and 15 
differs from the first one that assesses what someone’s health status allows to 
be completed when requested and under ideal circumstances. This checklist-
based system itself can be used as an outcome measure in rehabilitation (20); 
however, its practicality and specificity has been criticized before (21, 22). Still, 
Figure 1 Model of the International Classification of Functioning, Disability and Health (ICF)- this is 
the World Health Organisation (WHO) framework for measuring health and disability. 
5 
 
in research, this taxonomic system allows the identification of relevant outcome 
measures and the reporting of results in a common language (23, 24).  
 
Kierkegaard et al. (25) performed a cross-sectional study aiming to describe 
and analyse self-related perceived functioning, disability and environmental 5 
factors related to disease severity in adults with DM1. A selection of 23 OMs 
with different formats was used to assess a wide spectrum of the ICF 
components. The number of impairments or restrictions identified ranged from 
one to 55 with a prevalence correlation to disease severity. Twenty per cent of 
participants perceived problems with 19 out of the 29 body-function categories 10 
assessed; excessive daytime sleepiness and muscle power were rated as the 
most common areas of burden (76-80%). More than 20% of participants 
perceived difficulties in 23 out of 52 activities and participation categories 
queried. Fifty-nine per cent to 74% reported difficulties in mobility-demanding 
activities. Finally, nine of the 23 environmental factors were identified as 15 
facilitators with family members and transport services as the most common 
(29-37%) with none were identified as barriers. This was the first attempt of 
classifying OMs according to the ICF checklist in DM1. These findings 
emphasize the multi-systemic nature of DM1 and the need for a 
multidisciplinary approach when caring and assessing patients with this 20 
disease. Indeed, Kierkegaard concluded her study by emphasizing the lack of 
standardized and validated OMs in the DM1 population and the possibility of 
developing a new disease-specific OM (26).  
 
1.4. FUNCTIONAL OUTCOME MEASURES IN DM1 25 
 
From 2011 a series of international workshops has been conducted with the 
purpose of selecting outcome measures (OM) suitable for RCTs in DM1. The 
Outcome Measures in Myotonic Dystrophy type- 1 (OMMYD) meetings pursue 
the filtered selection of condition-specific outcome measures recommended for 30 
longitudinal studies and potentially randomized controlled trials (RCTs) in DM1. 
These meetings started by defining a core set of disease-related domains 
recommended to be measured (i.e. quality of life, muscle strength, cognition, 
fatigue and daytime sleepiness and functional autonomy). This was followed by 
the identification of available evidence-based OM that could fit on any of the 35 
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core set domains; the pre-defined criteria for an ideal OM included: [a] the test 
must be valid, reliable and sensitive to change; [b] normative data should be 
available; [c] good test-retest reliability; and, [d] simple to administer (27). After 
that, continuous investment towards the experimentation, validation and 
methodology standardisation of these outcomes has been made (27, 28). This 5 
expert-lead consensus process has followed the methodology of the Outcome 
Measures in Rheumatology initiative (OMERACT)(29-31). 
 
In 2011, the group in charge of the Functional Capacity Outcome Measures 
(FCOM) (i.e. upper and lowed extremity functions) agreed that the selected set 10 
of outcomes should measure the reflection of daily life movements and 
capacities and the domains proposed included: balance, walking capacity, 
global lower extremity function, dexterity and upper extremity speed and 
function (27). Due to the early stages of the DM1 research field in this domain, 
the FOM selection focused only on two criteria: [a] the OM must have sound 15 
metrological properties, according to the OMERACT filter (29); and [b] it must 
be easy to administer in research and in clinical practice among different 
countries (27); after this, it was agreed that further experimentation should 
follow. From an initial set of suitable FCOM (Table 1), five were considered as 
most appropriate for DM1 based on published evidence and team members’ 20 
experience with the disease and the different outcomes discussed. The final set 
of proposed FCOM included: (1) Six-Minute Walk Test (6MWT), (2) timed 10-
Meter Walk Test (10m-WT), (3) timed 10-Meter Walk/Run Test (10m-W/RT), (4) 
30-Second Sit Stand Test (30SSST), and (5) Nine-hole Peg Test (9HPT)(28). 
On the last OMMYD meeting in 2015, the FCOM team suggested standardizing 25 
operational procedures (SOPs) for a set of identified outcomes relevant when 
assessing physical capacity in DM1 clinical trials. Details of the FOM selection 
process are presented in chapter 3. 
 
1.5. CURRENT CLINICAL TRIALS IN DM1 30 
 
By 2017, ClinicalTrials.gov shows 77 registered studies, 59 assessing a type of 
intervention with 15 studies actively recruiting. Functional outcome measures 
(not related to the PHENO-DM1 trial) identified were: 10-m walk and walk/run 
test (ClinicalTrials.gov Identifier: NCT02858908 and ClinicalTrials.gov 35 
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identifier: NCT00577577), 6MWT (ClinicalTrials.gov Identifier: 
NCT02118779) and TUG (ClinicalTrials.gov Identifier: NCT02312011 and 
ClinicalTrials.gov Identifier: NCT02251457).   
 
ClinicalTrials.gov Identifier: NCT02858908 is a single-bling, phase II study to 5 
evaluate the safety and efficacy of Tideglusib in adolescent and adult subjects 
with congenital or juvenile-onset myotonic dystrophy type 1. Tideglusib is a 
selective and irreversible GSK-3β inhibitor with therapeutic potential already 
identified in other pathologies (32, 33). GSK-3β or glycogen synthase kinase 3 
is a protein responsible for the phosphorylation and regulation of different 10 
factors of the transcription process and is involved in the regulation of the cell 
cycle, apoptosis, and survival (34). In DM1, there is an increase in stability and 
activity of the GSK-3β (35).  Preliminary findings indicate that Tideglusib may 
act on the central nervous system, however due to the molecular level of action 
and preclinical findings, it might also be beneficial for muscle function in patients 15 
with DM1 (35). The 10-mWT and the 10-mW/RT, if adequate, should identify 
these changes, if any.  
 
ClinicalTrials.gov identifier: NCT00577577 is a phase II RCT study to 
evaluate the safety and efficacy of a complex of Recombinant Human Insulin-20 
Like Growth Factor In Myotonic Dystrophy Type 1. The insulin-like growth factor 
has shown protein synthesis and differentiation of DM1 muscle cells in culture 
(36). Ambulation and muscle function and strength are part of this study primary 
outcomes, the first one measured with the 10-mWT. 
 25 
ClinicalTrials.gov Identifier: NCT02118779 is the OPTIMISTIC trial which will 
be introduced later on in this chapter. 
 
ClinicalTrials.gov Identifier: NCT02312011 is a phase 1/2a blinded study 
testing safety, tolerability, and pharmacokinetics of multiple escalating doses of 30 
IONIS-DMPK-2.5Rx administered subcutaneously to adult patients with DM1. 
This is antisense-based compound targeting the toxic RNA translated from the 
mutated DMPK gene in the muscle. From preliminary findings there is small but 
encouraging trend in biomarker and splicing changes, therefore Ionis has 
reported a setback on the program until improved compound is ready (11, 37).  35 
8 
 
 
ClinicalTrials.gov Identifier: NCT02251457 is a phase II study to determine if 
ranolazine is a safe and effective treatment for the symptoms of myotonia 
congenital, myotonia congenita, and myotonic dystrophy type 1. As primary 
outcomes this study included: [1] patient reported outcomes related to quality of 5 
life; [2] electromyography to measure myotonia; and, [3] the time up and go 
(TUG) test as muscle task. Preliminary findings identified significant changes 
after four weeks of treatment with a TUG time reduction (p = 0.03) (38).  
 
 10 
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Table 1. Functional capacity outcome measures (FCOM) identified as suitable to introduce in DM1 clinical trials in 2011 by the OMMYD 
consortium. 
FCOM Characteristics Published Evidence with DM1 
6-minutes 
walking test 
(6MWT) 
Total distance walked over 6 
minutes as sub-maximal 
walking speed. 
Evaluates walking capacity and 
aerobic capacity. 
The difference for a single subject should be greater than 33 m or 6% of total 
distance to be considered a real clinical change (39).  
Thirty-seven children with congenital DM performed the first 2 minutes of the 
6MWT and showed correlation with leg lean mass muscle (r 0.62) (40). 
10-meters 
walk test (10-
mWT) 
 
Assesses walking speed at a 
selected comfortable pace.  
In older adults most small meaningful changes are from 0.04 to 0.06 m/s on 
gait speed. 
Even though selected walking speed in the clinical environment might still be 
slower than selected speed when tested in the daily life environment this test 
differentiates disease severity (41). 
10-meters 
walk/run test 
(10-mW/RT) 
Assesses walking speed at 
fastest possible pace. 
This test has been studied as a possible fall predictor in DM1 (42-44). 
 
Timed Up & 
Go (TUG) 
Time it takes a patient to rise 
from a seated position in an 
armchair, walk 3 metres at 
After five years of follow-up DM1 patients showed a statistically significant 
(p<0.001) deterioration (from 9.6 secs at baseline to 12 secs at year 5) (44, 45). 
This test correlates to falls risk in DM1. 
10 
 
selected speed, turn back and 
sit down. 
In the elderly, it differentiates between fallers and non-fallers in older people 
(cut off >14 seconds) (46). 
Step Test As many “full steps” as possible 
over an 8 cm high block.  
 
After 5 years of follow up, a mean reduction of 19% was observed in DM1 
patients (45). 
It has been correlated with the number of falls a patient may experience in one 
year 
30 seconds 
sit and stand 
(30SSS) 
Measures functional lower limb 
strength and dynamic balance. 
Reliability and validity studies not yet published for DM1. 
A similar test, timed-stand test (TST) has been suggested to separate normal 
from abnormal performance on adult muscular conditions, but has the risk of 
excluding participants on the more severe spectrum of the phenotype that could 
not perform the test (i.e. Muscular Impairment Rating Scale of 4 or 5) (25, 47). 
Nine-hole 
Peg test 
(9HPT) 
Assesses upper extremity 
function, specifically fine 
dexterity. 
Good to very good intra- and inter-reliability were reported in adults with DM1 
(48). 
Discriminates between participants with distal weakness or non weakness at 
all and participants with weakness present in proximal muscles (i.e. Muscular 
Impairment Rating Scale stages 1-3 and 4-5) (47). 
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1.6. ACCELEROMETERS: POTENTIAL OUTCOME MEASURES OF 
PERFORMANCE IN DM1 
 
All the previous mentioned FCOMs are examples of capacity assessments. 
There are, however, other options to assess directly and objectively: matters 5 
of performance. By accurately measuring physical activity in a free-living 
environment, someone’s functional performance in daily life can be assessed 
(19, 49). The ICF considers the individual’s PA levels and participation 
alongside the individual’s environment as factors to consider when classifying 
someone’s health status. 10 
 
Current technology allows for measuring activity behaviours with good 
accuracy and detail and an example of this is the use of accelerometers (50). 
Accelerometer outputs come from detecting and recording body acceleration 
and deceleration and are usually recorded as units of acceleration over time 15 
(counts) that can then be further transformed into more meaningful outputs 
such as energy expenditure or step counts. Despite advances in the use and 
development of accelerometers, careful consideration is still needed when 
employing them to capture clinically meaningful outcome measures (51). 
When thinking about activity monitors (in this case accelerometers) for 20 
cohorts accompanied by functional limitations such as DM1, certain factors 
should be considered to support and validate the application of a device in the 
population of interest such as altered biomechanics and a slower gait speed 
when walking (52, 53). Increasingly, this technology has been implemented 
into research and many of these tools have been correlated to long-term 25 
health outcomes and motor capacity in diseases with impaired mobility such 
as Parkinson’s disease (54), stroke (55) and cerebral palsy (56). Their use 
and interpretation in DM1 and other neuromuscular disorders are still in their 
infancy (51, 57).  
 30 
1.7. CHARACTERISTICS OF A GOOD OUTCOME MEASURE 
 
Any outcome measure gives the opportunity to assign a number to an 
observation and to quantify a phenomenon (58). When choosing measures or 
12 
 
tools as relevant OMs for any population in particular, in this case DM1, it is 
important to consider the assessment properties: validity, reliability and 
responsiveness, plus the feasibility of its implementation (59). 
 
Reliability: defines the accuracy level of a measurement. A significant 5 
component of the process of development or validation of an outcome 
measure is to reduce the error of measurement as much as possible. A good 
outcome measure will be reliable not only within the test in particular but at 
different times or when performed by different assessors also (58, 59). 
Internal reliability can be measured by the Cronbach’s Alpha obtained from 10 
the Intraclass Correlation Coefficient (ICC) measurement; and, by comparing 
two different scores either from test to test or from one tool to another external 
reliability can be estimated (60-62).  
 
Validity: reflects the extent to which an instrument measures what it is 15 
supposed to measure. By correlating an outcome measure to other validated 
tools or scores in the same area we can validate the level of comparability 
within measures (63, 64).  
 
Sensitivity: is the ability of a test to correctly classify an individual as 20 
‘affected’ (or characteristic present) (65). 
 
Specificity: is the ability of a test to correctly classify an individual as 
characteristic-free (65). 
The specificity and sensitivity probabilities of a test or its accuracy to 25 
discriminate different disease cases from others (or from clinically unaffected) 
may be evaluated using Receiver Operating Characteristic (ROC) curve 
analysis (65-67). 
 
Responsiveness: is the ability of a measure to detect any real change over a 30 
prespecified time frame. With progressive diseases, a longitudinal analysis 
can test an outcome measure’s sensitivity to change and can help to establish 
the minimum change to be considered as a clinically meaningful change over 
that specific period of time (68).  
13 
 
 
There might already be other outcome measures that quantify the same or 
very similar characteristics to the one expected, but, if there is not enough 
evidence of the reliability and validity of these in the specific targeted 
population then this measure should be initially tested and validated in the 5 
population of interest before implementing it in a clinical trial (58, 59).  
 14 
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CHAPTER 2. STUDY OUTLINE 
 
2.1. GENERAL AIM 
 
The aim of this research is to explore outcome measures and assess 5 
functional capacity and performance in adults with myotonic dystrophy type 1 
(DM1), searching for tools and data that maybe suitable for use in clinical 
trials. 
 
2.2. SPECIFIC AIMS 10 
 
1. To explore the feasibility, validity and reliability of the OMMYD selected 
functional outcome measures: 30 seconds sit and stand, 10 meters 
walk test and 10 meters walk/run test; in adults with DM1. 
2. To explore the validity and feasibility of activity monitors 15 
(accelerometers) as outcome measures of daily life performance 
(habitual physical activity) in DM1 adults. 
3. Describe assessment protocols for the selected outcomes that can be 
replicated in clinical practice and/or clinical trials.  
4. Describe a source of reference values that can help the design of 20 
future clinical trials selecting any of the above as an outcome measure 
of their study.  
 
2.3. THESIS HYPOTHESIS 
 The functional capacity of DM1 adults can be assessed 25 
effectively with the following functional outcome measures: 30 
seconds sit and stand, 10 meters walk test and 10 meters 
walk/run test. 
 With the use of ankle-worn accelerometers, we can objectively 
measure habitual physical activity of patients with DM1. 30 
 
2.4. STUDY DESIGN 
 
 16 
 
The results presented in this thesis are derived in their majority from two on-
going trials in DM1: [1] OPTIMISTIC (ClinicalTrials.gov Identifier: 
NCT02118779), and [2] PHENO-DM1 (ClinicalTrials.gov Identifier: 
NCT02831504). Both studies target genetically confirmed DM1 adults with the 
former study an intervention based randomised control study; and the second 5 
one, a natural history observational study. Additionally, two other cohorts were 
included in study 1 as comparisons groups, one formed by healthy volunteers 
and another formed by chronic fatigued patients (Figure 2. Thesis outline).  
 
The first study (chapter 3) focuses on the OMMYD selected functional 10 
outcome measures (FOM) and the second study (chapter 4) investigates the 
use of an accelerometry-based device (GeneActiv accelerometers) in DM1 
adults. Both studies start with an initial description of the sample as a cross-
sectional single-visit study followed by a smaller -sample longitudinal analysis. 
 15 
The statistical methodology followed by both studies is very similar including 
both a set of the following: [1] descriptive statics and normality testing 
(Shapiro-Wilk test); [2] comparison between groups and sub-groups 
(independent sample t-test and Mann-Whitney test); [3] reliability and validity 
testing with the use of intraclass correlation tests, binary correlations and 20 
Bland-Altman plotting; and, [4] progression over time analysis (paired T-test) 
and standard error of measurement (SEM) estimations to identify a minimum 
expected change when declaring a real change. Additionally, a Receiver 
Operating Characteristic (ROC) analysis was performed for the FOM chapter.  
 25 
Specific details of each study are presented in their respective chapters.  
 
 
 
 30 
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Figure 2. Thesis outline. 
 5 
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2.4.1. OPTIMISTIC trial (ClinicalTrials.gov Identifier: NCT02118779) 
 
Observational Prolonged Trial in Myotonic Dystrophy type 1 to Improve Quality 5 
of Life Standards, Target Identification Collaboration (OPTIMISITC). 
OPTIMISTIC is a two-arm, multi-centre, randomized controlled trial with the 
main aim of improving clinical practice in the management of patients with DM1. 
It has been designed to compare standard management regimes against an 
active group. The active component is based on a cognitive and behavioral 10 
change therapy (CBT) developed particularly to increase physical activity as it 
includes a special component of graded physical activity. OPTIMISTIC is the 
first international clinical trial in myotonic dystrophy type 1 as collaboration 
between: the Netherlands, Germany, Paris and Newcastle, with one recruitment 
site in each (69).  15 
 
The rationale behind this study intervention comes from the importance and 
prevalence of severe fatigue (>70%) in DM1 (70). Severe fatigue is a 
perpetuating factor that impacts on people’s social participation and quality of 
life. After a DM1 longitudinal study, a fatigue model was created; this showed 20 
associations between reported fatigue and lack of physical activity, sleep 
disturbances, pain and the disease-associated lack of motivation of these 
patients. It was concluded that by alleviating at least one of these influencing 
factors, experienced fatigue or the way the patient copes with it could be 
improved and by consequence their general health status and quality of life (71, 25 
72). 
 
This study aim will be assessed by the impact on the DM1-ActivC patient 
reported outcome (73) (as primary outcome) and with a wide range of 
secondary outcomes that include: fatigue reported outcomes (Checklist 30 
Individual Strength (CIS) fatigue score); 6-minute walk test (6MWT); and, 
Habitual Physical Activity (HPA) levels measured for 15 consecutive days after 
each visit by using an ankle worn tri-axial accelerometer (GENEActiv). All 
outcome measures (or as many as possible), together with any adverse events 
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will be measured at screening/baseline visit (i.e. combined visit 1 and 2), visit 3 
(5 months), visit 4 (10 + 1 months) and visit 5 (16 + months)(69). 
 
The inclusion criteria include adult patients (≥18 years), who are severely 
fatigued (as measured with a CIS score ≥35), with the ability to walk 5 
independently (orthotics and walking assistive devices allowed) and capable to 
provide informed consent. 
 
2.4.2. PHENO-DM1 trial (ClinicalTrials.gov Identifier: NCT02831504) 
 10 
PHENODM1- Myotonic Dystrophy type 1 (DM1) includes deep phenotyping to 
improve delivery of personalized medicine and assist in the planning, design 
and recruitment of clinical trials.  PHENO-DM1 is a multicentre (Newcastle and 
London), natural history study in the UK that has completed recruitment and 
baseline assessments. PhenoDM1 will use patient reported outcomes to assess 15 
levels of pain, fatigue, quality of life and disease burden in this cohort. Clinical 
and functional outcomes will look at muscle wasting and levels of myotonia and 
blood samples (RNA, DNA, HbA1c, thyroid hormones and androgens in males) 
will be collected from all patients so that additional genetic and molecular 
biomarker analysis can be performed.  20 
 
Inclusion criteria limited to those over 18 years of age, with a genetic 
confirmation of DM1 who are able to provide informed consent and walk for at 
least 10 meters independently (orthotics and walking assistive devices allowed). 
One of the aims of this study is to identify population subgroups and understand 25 
independently the nature of disease-progression in different phenotypes. This 
unrestrictive approach will enable the assessment of a wide and comprehensive 
spectrum of the population, including those with early, adult and late onset 
phenotypes.  
 30 
This study aimed to recruit 200 to 400 patients with a 1:1 men and women ratio. 
It involves two to three study visits approximately 12 months apart.  
Strength and function assessments include: [1] Manual muscle testing and 
Quantitative Muscle Testing (Hand Held Myometry and Hand-Grip 
Dynamometry; [2] Muscular impairment rating scale (MIRS)(74); and [3] 35 
 20 
 
Functional outcome measures (FOM) in parallel with OMMYD agreement (Nine 
Hole Peg Test, Six Minute Walk Test, 30 Seconds Sit and Stand Test, Timed 
10-Meter Walk Test and timed 10-Meter Walk/Run Test). 
 
2.5. SAMPLE RECRUITMENT AND CHARACTERISTICS 5 
 
The two main sources of patient recruitment for these trials were the UK 
Myotonic Dystrophy Patient Registry (75) and directly at clinics when attending 
their standard annual specialist appointment. The Myotonic Dystrophy Patient 
Registry in the UK is a nationwide, self-completed system where DM patients 10 
can register and provide basic information of their condition and consent to be 
approached in case suitable clinical trials. It also includes a section filled in by 
the health-professional involved with the participant with a brief understanding 
of their disease-status allowing identification of potential participants based on 
characteristics matching trial selection criteria. However, strategies aimed at 15 
raising awareness through patient organizations or at platforms at 
neuromuscular diseases conferences were also implemented. Implementation 
of these strategies has provided me with an unprecedented number of DM1 
participants for my studies.  
 20 
 
2.6. ETHICAL APPROVAL 
 
The collection of data from each cohort is under the ethical approval of the 
corresponding study protocol. 25 
 
OPTIMISTIC (IRAS project 137613) has been funded by the EU Seventh 
Framework Programme (#305697) and has been ethically approved by the 
NRES committee North East – Tyne & Wear South (REC: 13/NE/0342) and 
developed in collaboration with The Newcastle upon Tyne Hospitals NHS 30 
Foundation Trust in the UK. Dr. Grainne Gorman is the principal investigator at 
Newcastle site. 
 
PHENODM1 (IRAS project 180510) has been funded by the National Institute of 
Health Research (NIHR) Rare Disease Translational Research Collaboration 35 
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and The Wyck Foundation and has been ethically approved by the NRES 
committee North East – Tyne & Wear South (REC: 15/NE/0178) and developed 
in collaboration with The Newcastle upon Tyne Hospitals NHS Foundation Trust 
under the lead of Professor Hanns Lochmuller and University College London 
Hospitals NHS Foundation Trust under the lead of Dr. Chris Turner. 5 
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CHAPTER 3. EXPLORING FUNCTIONAL OUTCOMES IN DM1 
 
3.1. INTRODUCTION 
 
Myotonic Dystrophy type 1 (DM1) is a multisystem disease with high 5 
heterogeneity, which represents an obstacle when defining outcome measures 
that can be valid for different phenotypes yet still be sensitive to address 
change over time. Novel emerging therapies for DM1 require a deep 
understanding of the natural progression of the disease through multifactorial 
assessment tools that can be applied to disease cohorts. The OMMYD 10 
Consortium has proposed a set of Functional Outcome Measures (FOM) that 
were highlighted for consideration in clinical trials for DM1 (27, 28). A cohort of 
213 patients was enrolled in the natural history study of PHENO-DM1 (Myotonic 
Dystrophy Type 1 Deep Phenotyping to Improve Delivery of Personalized 
Medicine and Assist in the Planning, Design and Recruitment of Clinical Trials) 15 
with the aim to assess the validity, reliability and possible sensitivity to change 
of three of the five OMMYD functional outcome measures (FOM). The protocol 
includes: [1] Standard medical history; [2] Strength assessments (myometry and 
manual muscle testing); [3] Functional outcome measures (six-minute walk test, 
30 seconds sit and stand test, timed 10 m walk test, timed 10 m walk/run test, 20 
9-hole peg test); and [4] patient-reported outcomes including the gold standard 
tools for DM1 (DM1-Activ-c and MDHI). By comparing selected functional 
outcome measures to clinical manifestations of the disease and to the reported 
burden of illness, we expect to establish the feasibility and validity of these tests 
in large-scale studies. By analysing the variability from each test retest we 25 
expect to assess their reliability and by stratifying our population according to 
sex or clinical phenotype, we expect to establish reference values for their use 
in clinical trials in DM1.  
 
SELECTING FUNCTIONAL OUTCOME MEASURES AS PART OF THE 30 
OMMYD CONSORTIUM 
 
As introduced earlier, the international OMMYD consortium was initiated with 
the aim of selecting the best available outcome measures to be used in 
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research and clinical trials in DM1. The team members of the Functional 
Capacity Outcome Measures (FCOM) have reached consensus of four tests 
considered relevant and robust enough to assess physical function and capacity 
in DM1. These tests are: [1] six-minute walk test (6MWT), [2] 30 seconds sit 
and stand test (30SSS), [3] timed 10 m walk test (10-mWT), [4] timed 10 m 5 
walk/run test (10-mW/RT), and, [4] 9-hole peg test (9HPT). The selection 
process resulting in these FCOM started in 2011 and for the last 18 months 
prior to this thesis writing, their standard operating procedures were developed.  
 
The FCOM selection process followed closely the OMERACT initiative, a data 10 
driven interactive process in which a group of relevant stakeholders from 
different fields of interest in DM1 participated to endorse valid, responsive and 
feasible health outcome measures/scales relevant to disease specific health-
domains(31). On the first meeting, an agreement on a minimum set of 
outcomes worthy to investigate further was reached. Presentations and 15 
discussions focused on potential outcome measures which were identified 
through an initial pre-meeting questionnaire. For this first meeting, five 
attendees conformed the FCOM group (initially named upper and lower 
extremity functions). The first step consisted of reviewing existing tools that 
could assess the established disease-domains related to upper and lower limb 20 
functionality. This was accomplished through a systematic literature review 
selecting tools previously used in DM1 or other diseases with similar 
characteristics.  It was agreed that at that point experts were unable to create a 
DM1-specific FCOM battery of tests due to the lack of validity assessments 
specifically reported for DM1. However, they produced a list of 24 potential 25 
FCOM (including balance tests) emphasising the strengths and weaknesses 
raised during the discussion (27). 
 
Two years a second meeting was convened with a team of six experts 
conforming the FCOM group. The aim of this second meeting was to reach 30 
consensus on the creation of a universally feasible battery of tests. This will be 
accomplished by refining the previously selected outcomes based on three 
component criteria: truth (validity), discrimination (sensitivity and specificity) and 
feasibility. After that, a minimum of three tests would be expected as 
consistently used in future clinical trials in DM1. A series of discussions around 35 
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the outcomes identified at OMMYD-1 resulted in a classification system for the 
tests defining them as: “must”, “highly recommended” or “to be evaluated”, 
based on their relevance when assessing an intervention in DM1 that may 
impact on patients’ functionality. Four outcomes were identified as “must” and 
are presented in this chapter. Two main criteria led to their classification 5 
including previous results reported in DM1 and published or presented 
opportunity to discriminate disease severity (i.e. discriminate MIRS stages 1-3 
and 4-5). Evidence of test-retest reliability (regardless of population tested) was 
essential. Finally, we focussed on identifying outcomes that represented a 
functional activity as close as possible to a daily life activity (28). Outcome 10 
measures such as climbing stairs, timed up and go (TUG) and the Berg balance 
scale were labelled as “highly recommended” but not considered a “must” due 
to their risk for either flooring or ceiling effect (76-78). The 30 second sit to 
stand (30SSS) however, which is a close assessment to the TUG but avoids 
any floor effects was also deemed appropriate as could potentially assess 15 
fatigue (79).  
 
On the third and final meeting, there was an initial confirmation of the 
consensus around the four FCOM previously selected and a critical review of 
any new evidence supporting or rejecting the decision. An initial draft of the 20 
procedures to follow when implementing these tools was developed taking into 
consideration specific characteristics of this disease and sites’ feasibility. The 
refinement of these SOPs have been an on-going process and the final version 
of the outcome of these endeavours will be submitted to a peer-reviewed 
journal at the end of this year.   25 
 
3.2. METHODS 
 
3.2.1. Sample 
 30 
This study sample represents 213 patients screened for the ongoing 
observational natural history PHENO-DM1 study. The inclusion criteria for this 
study included a cohort of genetically confirmed DM1 participants 18 years old 
or older, with the ability to provide individual informed consent and walk 
independently (assistive devices and orthotics allowed) for at least 10 metres. A 35 
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cohort of 34 of these patients had completed a follow-up visit (12 months after 
baseline) at the time of this analysis and were included for progression-over-
time analysis.  
 
3.2.2. Procedures 5 
 
This research is covered under the ethical approval of the PHENO-DM1 study 
by The Newcastle and North Tyneside Ethics committee (Reference: 
NE/15/0178). 
 10 
This study focuses on the validity and reliability of the following functional 
outcome measures (FOM): [1] thirty seconds sit and stand (30SSS); [2] ten 
meters walk test (10-mWT); and [3] ten meters walk/run test (10-mW/RT). The 
following outcomes were considered for comparisons: [1] muscle strength and 
capacity (including: quantitative muscle testing (QMT) of hand-grip strength, 15 
knee extensors; hip flexors and ankle dorsiflexors, plus the Muscular 
Impairment Rating Scale (MIRS) which is a method of assessing disease 
progression as measured by muscle weakness manifestations (74); [2] 
additional performance tests, including the six-minute walk test (6MWT) and 
severity of ataxia rating scale (SARA) which assess balance and movement co-20 
ordination and have been reported as possible assessments of disease severity 
in DM1 (39, 42); [3] disease-specific patient-reported outcomes (PROM) which 
include the DM1-Activ-c Rasch built scale and the Myotonic Dystrophy Health 
Index (MDHI) questionnaire (73, 80, 81). 
 25 
The standard operating procedures (SOPs) for each test were discussed prior 
to submitting the protocol and those tests selected from the OMMYD pack 
attempted to follow the SOPs discussed at the OMMYD’s last meeting (Paris 
2015). The final consensus of these FOM were not finalized nor published at 
the time that this protocol was submitted (27, 28), hence, minor variances with 30 
these final SOPs can be identified.  
 
The following section describes the assessment methods: 
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30 second chair sit and stand test (TSST): this test measures the functionality of 
lower limb, core muscles’ strength and dynamic balance (82).  
 
Equipment used: [1] a chair 45 cm high with no armrests collocated straight 
back towards a firm wall and [2] a stopwatch. 5 
 
Procedure: the test starts with the patient sitting down; back straight and arms 
crossed against his/her chest, and is instructed to keep the arms in that position 
throughout the test. The patient is instructed “This test is called the 30 seconds 
sit and stand test, therefore you’ll have to do as many sit and stands as possible 10 
within 30 seconds. You’ll start when I say ‘go’ and you’ll do as many repetitions 
as possible until I say ‘stop’. It will have to be a full-stand (i.e. extended knees) 
for me to count it. Any questions? Are you ready to start?” The number of times 
the participant reaches the full standing position are counted. If the patient could 
not perform the test and needed arms support to complete the stand, “0” stands 15 
were recorded.  
Three full trials were attempted. Before starting each new trial the participant 
was asked “Are you feeling OK?” or, “How do you feel for another try?” and if 
the answer was “no”, the test would stop. 
 20 
10 meters walk test (10-mWT): this test measures the short duration of a 
comfortable walking speed (i.e. self-selected pace) (83). This test has been 
validated among a wider range of conditions and promises generalizable 
conclusions (84). 
 25 
Equipment used: [1] stopwatch and [2] a walkway of 12 metres of walking 
course, leaving one metre at the beginning for acceleration before the time-start 
point and at least 1 metre at the end after the time-end point for deceleration.  
 
Procedure: the test starts with the patient standing still at the first mark and 30 
receives the following instructions: “This is the 10 meters walking test and you 
are going to walk at a comfortable speed from this mark (or cone) to the one at 
the end of the line (indicating the last mark). Remember it is a comfortable 
speed, it means the normal speed you choose in your daily life activities”. The 
time recorded is from the moment the first foot of the patient crosses the second 35 
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mark to the moment the first foot crosses the third mark (10 metres). This 
means that is a timed 10-meter walk test at comfortable speed with flying start 
and flying finish.  
There is a standing rest (10-20 sec approx.) before asking the patient to repeat 
the same procedure aiming for 3 trials if possible. 5 
If the first two trials showed consistent results it was up to the assessor’s 
judgment to decide to go for a third trial or not.  
 
10 meters walk/run test (10-mW/RT): this test measures the participant’s ability 
to run and the maximum speed pace (83).  10 
 
Equipment, corridor length and measurement methodology are as the 10-mWT 
but with the following instructions: “This is the 10 meters walk and run test and 
the aim is for you to go from this mark (first) to that last one as fast as you can 
safely go. If you feel you can run you can. You’ll have more than one trial 15 
allowing you to test the surface on the first attempt. Remember it is safe”. 
 
Muscular Impairment Rating Scale (MIRS): is an ordinal five-point rating scale 
established according to the clinically recognized muscle strength loss 
progression from distal to proximal (74). This test has been proposed to monitor 20 
disease progression and has been used as disease-severity classification 
system in other trials exploring outcome measures in DM1 (39, 44).  
The scale grades are as followed: 
1. No muscular impairment 
2. Minimal signs (myotonia, jaw and temporal wasting, facial weakness, 25 
neck flexor weakness, ptosis, nasal speech, no distal weakness except 
isolated digit flexor weakness) 
3. Distal weakness (no proximal weakness except isolated elbow extensor 
weakness) 
4. Mild to moderate proximal weakness 30 
5. Severe proximal weakness (i.e. a proximal muscle with an MRC score 
≤3/5; MRC: Modified Medical Research Council Scale) 
 
6-minute walk test (6MWT): based on the proposed American Thoracic Society 
guidelines (85, 86), the 6MWT was performed with the following variations: [1] 35 
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corridor length of 25 metres (87); and [2] one examiner at each end of the 
corridor, and when considered needed (i.e. risk of falls or an unstable patient) 
one examiner walking behind the patient. Encouragement inputs were provided 
every minute. 
 5 
Severity of Ataxia Rating Scale (SARA): this test regardless been originally 
created as an ataxia rating scale (88), it has been identified as reliable and valid 
when measuring disease severity in DM1 with strong correlations to disease 
biomarkers (CTG length), strength and functional outcomes and to disease-
specific reported outcomes (42). The SARA test includes eight performance-10 
based items, each with different scoring ranges, but to all of them it applies that 
zero implies no dysfunction and higher scores imply a degree of impairment, 
with a total score between 0 and 40 (88).  
 
Exploring the utility of SARA as scale to measure disease severity has been a 15 
parallel project of this study and the first exploratory results have already been 
published (appendix A) (42). 
 
Quantitative Muscle Strength (QMT): the MicroFet-2 (MicroFet, Draper, UT) was 
used to assess the isometric strength of the following muscle groups: ankle 20 
dorsiflexors, knee extensors and hip flexors. All these measure in pounds (lbs). 
A Saehan DHD-2 Digital dynamometer was utilized to measure grip strength, 
measured in kg. Initial training for each examiner and standard written 
instructions were utilized throughout the assessments to increase intra-rater 
reliability. Each test was performed at least three times, searching for a 25 
variance of no more than 10% between tests but if the participant’s score 
continued increasing or one of the results was a big outlier, a fourth trial would 
be performed to confirm uniformity. The highest score within the 10% variability 
options was considered for this analysis.  
 30 
Rasch-built DM1-ActivC scale: a 25-item rasch-built scale that measures DM1 
patients participation level in daily life activities based on the ICF concepts of 
functioning and disability. Has proven high internal consistency and good tes-
retest reliability. Correlates with manually-tested muscle strength and to MIRS 
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score (73, 89). This questionnaire has been selected as the primary outcome on 
the OPTIMISTIC trial (69). 
 
The Myotonic Dystrophy Health Index (MDHI) questionnaire: is a disease-
specific- patient reported outcome instrument created under guidance from the 5 
FDA. Composed by 114-items each one representing a possible symptom of 
the disease. Scores from zero to 100 with the higher the score the higher the 
reported disease severity. There is evidence of excellent test-retest reliability 
and of sensitivity and specificity to differentiate DM1 severity. On the validation 
study, fatigue was the symptom with the highest mean scoring and the biggest 10 
difference shown between groups was between the employed and the 
unemployed (80, 81, 90). The MDHI is currently being used as a patient 
relevant outcome measure in clinical trials including the Phase II IONIS-
DMPKRx Therapeutic Treatment Trial for DM1 adults and as secondary 
outcome on natural history studies in the United States and on the OPTIMISTIC 15 
trial.  
 
Inter-rater reliability: aiming to reduce inter-rater variability as much as possible 
the following strategies were implemented: [1] SOP for each of the FOM and 
strength assessments were redacted including pictures of the participant and 20 
examiner positioning; [2] an initial training session for each of the assessors 
involved was led by the site’s lead physiotherapists who have wide experience 
in muscle strength assessment in neuromuscular conditions and clinical 
research training standards looking for an inter-rater agreement level 
considered “satisfactory” in the eyes of the trainer; and, [3] manual muscle 25 
testing and QMT were performed three times consecutively looking for a 
difference between scores no bigger than 10% and when this happened a 
fourth assessment was performed. This methodology replicates strategic 
procedures commonly used by physiotherapists when performing clinical trials 
in other neuromuscular disorders such as Duchenne Muscular Dystrophy and 30 
Spinal Muscular Atrophy (91-94). 
 
3.2.3. Statistics 
 
 31 
 
Normality was tested by utilizing the Shapiro-Wilk test. Independent samples (t-
test and Mann-Whitney U-test) were used to analyse differences between 
subgroups and for the Bland-Altman analysis. Correlation tests are presented 
as Pearson’s rho scores and scores ≥0.50 have been highlighted as strong 
values (95).  5 
 
Intraclass correlation coefficients (ICC2,1) were tested for test-to-test relative 
reliability (60). The paired t-test and Mann-Whitney test were used for 
differences between tests and over time and to assess responsiveness over 
time (96).  10 
 
Bland-Altman plots were used to check the distribution of the difference 
between scores and the agreement level between tests, identifying any possible 
systematic bias (63).  
 15 
Receiver operating characteristic (ROC) was used to test accuracy and to 
determine any possible cut-off points with optimal sensitivity (proportion of true 
positive results) and specificity (proportion of false positives). In a ROC curve 
the sensitivity is plotted as a function of the false positive rate (100-specificity) 
for different cut-off points. Each point representing a sensitivity/specificity pair-20 
ratio that matches to a particular outcome-result threshold-score. A test with 
perfect discrimination (no overlap between sensitivity and specificity 
percentages to distinguish the presence or absence of a defined characteristic) 
has a ROC curve that passes through the upper left corner. Therefore the 
closer the ROC curve is to the upper left corner, the higher the overall accuracy 25 
of the test (65, 66). The area under the curve (AUC) from this test then identifies 
participants with or without certain characteristics (e.g. disease or not, or 
disease sign or not); the closer to 1 the better discriminative ability the test has 
(97). In this study, the FOM have been tested for specificity and sensitivity to 
detect the following two outputs (or disease characteristics): ROC [1] 30 
participants with a SARA score of eight or above; and ROC [2] participants with 
proximal weakness (i.e. a MIRS score of IV or V). 
 
Standard error of measurement (SEM) and SEM% were used to determine the 
limit needed for the smallest change in a group mean to be considered a real 35 
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clinical change. SEM is the within-subject standard deviation (square root of the 
within-subject variance) (98).  
SEM=SD√(variance within scores) 
SEM=SD(√(SD21+SD22+SD3n/n) 
SEM%=SEM/mean of means *100 5 
 
For sample size calculations, the standard deviation (SD) at 12 months was 
multiplied by √(1 − r2) to estimate for a sample size robust enough to detect a 
significant change in a randomised controlled trial if any of these FOM are 
selected as primary outcomes (99). Correlation, ICC, ROC and SEM scores 10 
presented are those obtained from estimations using the average of the three 
trials of each FOM. For all results, only p values ≤0.05 have been considered 
statistically significant and rest are shown as ns (non statistically significant). 
 
3.3. RESULTS 15 
 
Two hundred and thirteen (n=213) participants were screened between the two 
sites, 110 in Newcastle and 103 in London. Data from three participants were 
excluded from the analysis due to significant missing data. Age and 6MWT 
were the only variables identified with a normal (i.e. Gaussian) distribution. 20 
There was a similar distribution of male and female allowing within-sex 
comparisons. Twelve per cent of the participants reported using a wheelchair 
either part-time (such as for long distances) or full-time in their daily life but 
none were wheelchair-dependent as all were capable of completing at least the 
10-mWT independently (orthotics or assistive devices allowed) as per inclusion 25 
criteria. The big majority of our sample (81%) presented with a MIRS score 
between II and IV, and the most commonly reported limitation to perform the 
functional tests was due to poor neuromuscular control, which included balance 
problems. Demographics are summarized in Table 3. 1. 
 30 
Table 3. 2 presents the strength and FOM results for the whole sample and 
between the sexes at visit 1 (baseline). Statistically significant differences 
between males and females were identified for all assessments except hand-
strength measurements. The 30SSS only showed significant differences 
between sexes when the best, the second and third trials were compared. 35 
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Table 3. 1 Participant's Demographics. 5 
  All   Male   Female   
N= 210   103 49% 107   
Age 45.1 
SD 
14.7 47 
SD 
15.3 43.3 
SD 
13.9 
Wheelchair users in DLA 26 12% 11 11% 15 14% 
MIRS              
I: no muscular impairment 22 10% 15 14% 6 6% 
II: minimal muscular 
impairment 58 27% 23 22% 36 33% 
III: distal weakness 46 22% 26 25% 20 19% 
IV: mild proximal weakness 67 32% 29 28% 38 35% 
V: severe proximal 
weakness 17 8% 10 10% 7 7% 
Walking accessory             
none 171 81% 83 80% 88 82% 
cane 26 12% 14 14% 12 11% 
crutches 2 1% 2 2% 0   
walker 2 1% 1 1% 1 1% 
Limiting Factors reported 
by examiner         
 
  
Pain 17 8% 6 6% 11 10% 
Poor Neuromuscular Control 34 16% 23 22% 11 10% 
Paresis 1 0%     1 9% 
Fatigue 10 5% 4 4% 6 6% 
Other 1 0%     1 1% 
N: number of participants per sample, SD: standard deviation, MIRS: 
muscular impairment rating scale 
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Table 3. 2 Strength values and Functional Outcome Measures (FOM) at baseline. 
 
Outcome Measure 
All   Male   Female 
 
sig. 
between 
sexes  
 Mean  SD Mean  SD Mean  SD  
SARA 5.4  4.6  5.7  4.8 5.1 4.3 ns  
Grip strength (QMT 
– kg) 16.8 12.8 19.8 15.3 13.9 7.7 ns 
Wrist Extensors 
(QMT – lbs) 15.6 8.4 17.3 10.3 14.0 5.8 ns 
Knee Extensors 
(QMT – lbs) 45.8 20.1 54.1 19.5 38.0 17.4 <0.001 
Ankle Dorsiflexors 
(QMT – lbs) 25.7 13.4 28.9 15.3 23.1 11.0 0.02 
Hip Flexors (QMT – 
lbs) 33.4 13.0 39.1 13.2 28.0 10.4 <0.001 
6MWT (metres) 415.4 148.7 440.4 155.7 389.9 138.1 0.02 
10-mWT (s) 9.9 4.4 9.3 4.1 10.5 4.6 0.008 
10-mWT 2nd Trial 9.6 3.8 8.8 2.6 10.4 4.5 0.002 
10-mWT 3rd Trial 9.5 4.3 8.4 2.6 10.4 5.0 <0.001 
Average 10m-WT 9.3 3.5 9.2 4.1 10.5 4.6 0.03 
Best 10m-WT 9 3.3 8.8 4 10 4.3 0.04 
Worst 10-mWT 10.2 4.6 9.5 4.1 10.9 4.9 0.03 
10-mW/RT (s) 6.1 3.4 5.4 3.4 6.8 3.3 <0.001 
10-mW/RT 2nd Trial 5.6 2.8 4.9 2.9 6.2 2.6 <0.001 
10-mW/RT 3rd Trial 5.4 2.7 4.5 2.6 6.2 2.6 <0.001 
Average 10-mW/RT 5.7 3.1 5.3 3.3 6.6 3.3 0.003 
Best 10-mW/RT 5.4 3.1 5 3.3 6.4 3.2 0.003 
Worst 10mW/RT 6.3 3.4 5.6 3.5 6.9 3.3 0.006 
30SSS (times) 10.7 6.1 11.2 6.6 10.2 5.5 ns 
30SSS 2nd Trial 13.4 5.6 14.2 6.0 12.6 5.1 0.05 
30SSS 3rd Trial 16.6 11.0 16.9 5.8 14.6 5.4 0.05 
Average 30SSS 11.5 6.5 12.1 6.9 10.9 5.9 ns 
Best 30SSS 13.4 6.2 14.4 6.6 12.4 5.7 0.03 
Worst 30SSS 10.5 6 11.1 6.6 10.1 5.5 ns 
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Total stands 
30SSS 30.7 20.2 32.4 21.4 29.1 18.9 ns 
SARA: severity of ataxia rating scale, QMT: quantitative muscle test, 6MWT: six-minutes 
walking test, 10-mWT: ten meter walk test (comfortable speed), 10-mW/RT: ten meter walk/run 
test (as fast as possible), 30SSS: 30 seconds sit and stand test, Total stands 30SSS: total 
stands accomplished in all completed test trials, SD: standard deviation, ns: not significant. 
 
 
There was a significant correlation between FOM, strength values and disease 
severity as scored by the SARA (r= 0.6 to 0.7, p<0.01) and the patient reported 
outcomes (PRO) (r=0.5 to 0.7, p<0.01) (tables 3.3a and 3.3b). There is a strong 5 
correlation between the four-selected FOM (r=0.6 to r=0.8, p<0.01). Age only 
correlated slightly but was significant with the 6MWT (r=0.1, p<0.05), 30SSS 
(r=0.2, p<0.01), and 10-mW/RT (r=0.2, p<0.01); with directions for each FOM 
suggesting a mild disease impact (i.e. less meters in 6MWT = higher age, more 
seconds in 10-mW/RT = higher age and less stands = higher age). 30SSS 10 
(following the 6MWT) (r=0.4 to 0.6, p<0.01) showed the strongest correlation 
values to muscle strength, in particular to lower limb strength (r=0.5, p<0.01) 
(Table 3. 3). Table 3. 4 shows the correlation values of the FOM with the PRO 
with significantly strong correlation values with DM1-ActivC overall score (r=0.6 
to 0.7, p<0.01) and with MDHI mobility (r=0.7, p<0.01) and ability to perform 15 
activities (r=0.6, p<0.01) sub-scales. From all FOM, the walking-capacity 
assessments (i.e.6MWT and 10-mWT) showed the strongest correlation values 
with the patient reported outcomes (r=0.6 to 0.7, p<0.01). Reported fatigue, 
pain, social performance and upper extremity functionality showed moderate 
association with all the FOM and the SARA score but with less strength to the 20 
10-mW/RT (r=0.4 to 0.5, p<0.01).  
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Table 3. 3 Correlations between FOM assessments and strength - Spearman's 
rho correlation coefficients. 
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 1
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-m
W
T
 
 1
0
-
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6MWT 
 
-.14* -.64** .59** .45** .47** .46** .51** 1.0     
10-
mWT 
ns .63** -.51** -.37** -.50** -.42** -.45** -.81** 1.0   
10-
mW/RT 
.21** .55** -.49** -.33** -.49** -.46** -.52** -.80** .81** 1.0 
30SSS -.2** -.67** .44** .47** .57** .52** .54** .69** 
-
.64** 
-
.65*
* 
*Correlation is significant at the ≤0.05 level (2-tailed) 
**Correlation is significant at the≤ 0.01 level (2-tailed) 
SARA: severity of ataxia rating scale, wrist ext.: wrist extensors quantitative muscle 
strength (QMT), knee ext.: knee extensors QMT, ankle dorsiflex.: ankle dorsiflexors 
QMT, hip flex.: hip flexors QMT, 6MWT: six minute walking test, 10-mWT: ten-
meter walk test (average of three trials), 10-mW/RT: ten-meter walk/run test 
(average of three trials), 30SSS: 30-seconds sit and stand test (average of three 
trials). 
Strong correlation rho values (≥0.50) 
 
   
Table 3. 4 Correlations between assessments and disease-specific patient 
reported outcomes (DM1-ActivC and MDHI questionnaires) - Spearman's rho 
correlation coefficients. 5 
Patient Reported 
Outcome 6
M
W
T
 
1
0
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3
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S
S
 
S
A
R
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 DM1-ActivC score .69** .67** .59** .65** .72** 
MDHI- mobility subscale .73** .73** .66** .65** .71** 
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MDHI-Upper Extremity 
Functionality subscale .49** .46** .38** .46** 
.54** 
MDHI-Ability to perform 
activities subscale .64** .62** .56** .57** 
.60** 
MDHI-Communication 
subscale .25** .26** .18* .28** 
.39** 
MDHI-Social satisfaction 
subscale .43** .42** .34** .43** 
.45** 
MDHI-Social performance 
subscale .45** .45** .36** .43** 
.45** 
MDHI-Fatigue subscale .50** .51** .43** .48** .45** 
MDHI-Pain subscale .54** .49** .44** .50** .47** 
MDHI-Myotonia subscale .52** .48** .40** .48** .52** 
MDHI-Gastrointestinal 
issues subscale .23** .26** .17* .30** 
.19** 
MDHI-Swallowing 
subscale .22** .25** .16* .28** 
.24** 
MDHI-Vision subscale .27** .28** .24** .31** .36** 
MDHI-Emotional issues 
subscale .33** .34** .26** .31** 
.37** 
MDHI-Sleep subscale .29** .35** .26** .33** .31** 
MDHI-Cognition subscale .22** .27** .21** .25** .25** 
MDHI-Hearing subscale .15* .15* ns ns ns 
MDHI-Breathing subscale .33** .33** .27** .34** .31** 
Total MDHI .56** .56** .46** .54** .55** 
*Correlation is significant at the ≤0.05 level (2-tailed)  
**Correlation is significant at the≤ 0.01 level (2-tailed)  
6MWT: six minute walking test, 10-mWT: ten-meter walk test (average of 
three trials), 10-mW/RT: ten-meter walk/run test (average of three trials), 
30SSS: 30-seconds sit and stand test (average of three trials), DM1-ActivC: 
Rasch-built DM1-ActivC daily life activities performance questionnaire, MDHI: 
myotonic dystrophy health index questionnaire, ns: not significant. 
Strong correlation rho values (≥0.50) 
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Participants reported their capability of running as part of the DM1-ActivC 
questionnaire that exhibited the following distribution: [1] not possible to perform: 
37%; [2] possible with difficulty: 27%; and [3] possible with no difficulty: 36%. 
These results were used to identify cut-off points to distinguish runners from non-
runners with the 10-mWT and the 10-mW/RT (Figure 3. 1). 5 
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Figure 3. 1 Patient reported capability to run. 
Figure 3.1a (10-mWT: ten meter walk test) and Figure 3.1b (10-mW/RT: ten 
meter walk/run test): data presented indicate the mean values per group with their 5 
12.7 ** 
95%CI 11.5-14 
** sig 
<0.001 
9.3 ** 
95%CI 8.4-10 7.6 ** 
95%CI 7-8 
5.6 ** 
95%CI 5.1-
6.2
3.9 ** 
95%CI 3.5-
4.3
8.8 ** 
95%CI 7.9-9.7 
** sig 
<0.001 
3.1a 
10-
mW
T 
and 
pati
ent  
3.1b 
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95% confidence intervals (95%CI). Groups were defined by participants’ reported 
capability of running.   
10-mWT, 10-mW/RT and 30SSS were attempted in three consecutive trials 
whenever possible. More than 90% of the participants capable of performing the 
test performed a second trial. If participants not capable of performing the 30SSS 5 
are scored as ‘zero’ on their first attempt, then 84% continue for a second trial; 
but, when only those capable of performing the test are considered, then 92% 
performed a second trial of the test. More than half of the participants completed 
the three trials of each test (Table 3. 5). The most common reason not to carry out 
a second or third trial was fatigue followed by fear of falling from either the 10 
examiners’ or participants’ point of view. Table 3. 5 presents the descriptive 
statistics per assessment trial for each FOM. More than half of the participants 
performed their best (or only) attempt at the first trial of the 10-mWT and the 10-
mRT. The 30SSS had a similar distribution between the trials but with the majority 
of the milder participants (i.e. MIRS I and II) scoring better at the second or third 15 
trial. The more severe participants (i.e. MIRS V) scored their best at the first 
attempt. There was a statistically significant change (p<0.001) from the first trial 
to the second on all three FOM and between the second and third trials of the 
30SSS (Table 3. 2). 
 20 
The ICC test revealed a very strong Cronbach’s alpha of: [1] 0.992 for the 10-
mWT; [2] 0.987 for the 10-mW/RT; and [3] 0.979 for the 30SSS. For the Bland-
Altman analysis, when the mean difference between the means was significantly 
different from zero (i.e. first vs. second trial of the 10-mWT, 10-mW/RT and 
30SSS and second vs. third trial of the 30SSS) a plot is not suitable as these 25 
measurements do not agree with each other. Between the second and the third 
trials of the 10-mWT and 10-mW/RT there was a mean difference of 0.04 (95% 
interval of agreement = -2 to 2.1) and 0.6 (95% interval of agreement = -1.1 to 
1.2) respectively (Figure 3. 2).  
 30 
ROC curve results showed that 30SSS and 10mW/T are good tests to 
discriminate between participants with a SARA score of eight or above and are 
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fair tests to discriminate between participants with proximal muscle weakness 
(Figure 3. 3). The 10mW/RT showed fairness for both of the outputs (Figures 3.3e 
and 3.3f). Table 3. 6 presents a range of suitable cut-off points when considering 
any of these FOM to predict the tested outcomes and those in bold have 
highlighted those considered more suitable for consideration based on a balance 5 
between sensitivity and specificity aiming for a sensitivity >60% and a specificity 
<40% and that could apply equally for both tested outcomes. For the 30SSS test, 
11 full stands are recommended as the most appropriate cut-off value. 
 
The results of the SEM (SEM%) estimations were: [1] 0.53 sec (5%) for the 10-10 
mWT; [2] 0.44 sec (8%) for the 10-mW/RT; and [3] 1.4 times (10%) for the 
30SSS. 34 participants assessed for a second time 12.1 (SD0.8) months after the 
baseline showed a significant disease progression as detected by all FOM in at 
least one score, the SARA and knee extensors strength (Table 3.6). All FOM 
showed at least one output with a significantly higher change score than the 15 
minimal expected SEM and SEM%. In order from more to less, the sequence of 
change from baseline (%) was: 1st SARA score (32%), 2nd total stands of 30SSS 
(26%), 3rd the best (22%), the average and the worst (21% both) 10-mW/RT, 4th 
the best 30SSS (19%), 5th average (16%), the best (15%) and the worst (14%) 
10-mWT and the average 30SSS (16%) and, last the 6MWT and the worst 20 
30SSS (13% both)(Table 3. 7).  
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Table 3. 5 Descriptive statistics and performance prevalence per trial for all FOM sub-divided by participant's MIRS score. Presented are: 
mean and standard deviation (SD) for each trial, prevalence (percentage) of participants performing the test at each trial and frequency 
(percentage) of participants performing their best at each trial. 
    1st trial 2nd trial 3rd trial Best of 
three 
  MIRS Part. mean SD % best 
best 
Part. mean SD % best Part. mean SD % best mean SD 
30
SS
S 
I 100% 16.2 6.0 10% 100% 18.1 6.9 38% 76% 19.1 5.8 52% 18.7 7.1 
II 100% 13.1 4.9 28% 96% 14.7 5.4 39% 68% 17.2 5.0 33% 15.1 5.7 
III 100% 11.1 6.3 39% 80% 14.5 5.1 28% 57% 15.9 5.6 33% 13.2 6.9 
IV 100% 8.5 4.3 35% 86% 10.4 3.4 34% 48% 11.6 4.4 31% 9.9 5.0 
V 100% 3.5 4.2 71% 47% 8.1 4.3 18% 18% 14.0 0.0 12% 4.4 5.4 
 N= 210 10.7 6.0 34% 177  13.4 5.6 33% 115  15.6 5.6 33% 12.5 6.9 
10-
m
W
T 
I 100% 7.0 1.1 45% 100% 7.0 1.2 32% 64% 7.1 1.4 23% 7.3 1.2 
II 100% 8.4 2.4 52% 98% 8.1 2.1 31% 76% 7.7 1.4 17% 8.6 2.4 
III 100% 10.2 4.2 52% 100% 10.0 4.1 35% 80% 10.1 4.7 13% 10.4 4.3 
IV 100% 11.2 4.6 52% 97% 10.9 4.5 34% 70% 11.1 5.1 13% 11.5 4.8 
V 100% 13.4 7.9 59% 88% 11.8 3.0 29% 47% 11.7 4.9 12% 13.6 7.8 
 N= 210 9.9 4.4 52% 205  9.6 3.8 33% 150  9.5 4.3 15% 10.2 4.6 
10-
m
W/
RT 
I 100% 3.3 1.4 77% 100% 3.0 1.4 23% 86% 3.0 1.3 0% 3.3 1.4 
II 100% 4.9 2.6 64% 97% 4.5 1.9 28% 81% 4.4 2.0 9% 5.1 2.7 
III 100% 6.3 3.4 57% 98% 6.1 3.2 30% 70% 5.9 2.4 14% 6.5 3.4 
IV 100% 7.3 3.5 58% 95% 6.7 2.5 23% 68% 6.9 2.7 19% 7.5 3.4 
V 100% 8.6 4.0 75% 69% 8.1 3.3 19% 50% 8.1 2.6 6% 8.8 3.9 
 N= 202  6.1 3.4 63% 191  5.6 2.8 25% 147  5.4 2.7 12% 6.2 3.4 
Part. column presents the percentages (%) grand total (N) of participants performing the test at each trial, mean: average score at 
each trial, SD: standard deviation, % best: percentage of participants performing their best test at each trial, MIRS: muscular 
impairment rating scale (I: no muscular impairment, II: minimal muscular impairment, III: distal weakness, IV: mild proximal 
weakness, V: severe proximal weakness), 30SSS: 30 seconds sit and stand, 10-mWT: ten meter walk test, 10-mW/RT: ten meter 
walk/run test.  
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3.2b. 10mW/RT – 2nd and 3rd trial 
3.2a. 10-mWT – 2nd and 3rd trial 
0.036 
-2.01 
2.06 
1.2 
0.62 
-1.1 
Figure 3.2a. Bland-Altman Plots between the (10-mWT) ten-meter walk test second and third trials; and, Figure 3.2b. 
Between the (10-mW/RT) ten-meter walk/run test second and third trials. 
Figure 3. 2 Bland-Altman Plots (identified agreement within test) between the second and third trial. 
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AUC:0.84 (95%CI 0.8-0.9) sig.000 AUC:0.83 (95%CI 0.8-0.9) sig.000 
AUC:0.78 (95%CI 0.7-0.9) sig.000 
AUC:0.77 (95%CI 0.7-0.8) sig.000 
AUC:0.73 (95%CI 0.7-0.8) sig.000 AUC:0.75 (95%CI 0.7-0.8) sig.000 
3.3a 3.3c 3.3e 
Figure 3. 3 ROC curves. 
Figures 3.3a to 3.3f. Receiver operating characteristics (ROC) curve to estimate cut-off points for identifying patients with the presence (sensitivity) or not (specificity) 
of the following outcomes representing disease severity: ROC 1 (top): a SARA score of 8 or above; and ROC 2 (bottom): proximal weakness (i.e. MIRS score of IV or V). 
3.3a and 3.3b: 30SSS (thirty-seconds sit and stand test); 3.3c and 3.3d: 10-mWT (timed ten-meters walk test); and, 3e and 3f: 10-mW/RT (timed ten-meters walk/run 
test. 
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Table 3. 6 Assessment cut-off values with respective sensitivity and specificity 
levels to identify the following outcomes: 
 [1] a SARA score of 8 or above; and [2] presence of proximal weakness 
measured by a MIRS score of IV or V. 
Test Outcome Cut Off Value Sensitivity Specificity 
30SSS SARA score ≥8 7.5 stands 49% 12% 
10.5 stands 82% 32% 
11.5 stands 94% 38% 
12.5 stands 98% 47% 
Proximal 
weakness 
7.5 stands 42% 11% 
10.5 stands 70% 31% 
11.5 stands 80% 38% 
12.5 stands 85% 46% 
15.5 stands 95% 69% 
10-mWT SARA score ≥8 10 secs 63% 15% 
9 secs 77% 28% 
8 secs 92% 48% 
7.9 secs 96% 53% 
Proximal 
weakness 
10 secs 52% 15% 
9 secs 65% 28% 
8 secs 87% 48% 
7 secs 95% 71% 
10-mW/RT SARA score ≥8 8 secs 47% 10% 
7 secs 58% 21% 
6 secs 73% 34% 
5 secs 84% 50% 
4 secs 96% 62% 
Proximal 
weakness 
7 secs 49% 18% 
6 secs 65% 33% 
5 secs 81% 46% 
2.7 secs 95% 77% 
30SSS: 30 seconds sit and stand test, 10-mWT: ten meter walk test, 10-mW/RT: ten 
meter walk/run test, SARA: severity of ataxia rating scale. In bold are presented the 
cut-off values considered most appropriate based on a balance of good sensitivity level 
and low specificity.  
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Table 3. 7 SARA, Strength and Functional Outcome Measures (FOM) 
progression over time. 
Results of a paired t-test analysis. 
Outcome 
Measure N= Mean SD 
Mean 
Change 95 % CI 
% from 
baseline 
sig. of 
change 
SARA 33 7.6 5.9 1.8 2.8 to 0.9 32% 0.00 
Grip strength 
(kg) 33 18.3 15.1 -0.4 2.0 to -2.8 2% ns 
Wrist 
Extensors 
(lbs) 32 15.8 9.1 0.2 1.9 to -1.4 2% ns 
Knee 
Extensors 
(lbs) 33 52.4 22.1 5.9 11.5 to 0.4 13% 0.04 
Ankle 
Dorsiflexors 
(lbs) 22 26.7 14.6 2.2 7.4 to -3.0 9% ns 
Hip Flexors 
(lbs) 27 37.6 11.7 4.0 10.3 to -2.2 12% ns 
6MWT 
(metres) 34 399.6 194 -45.7 -17 to -75 -10% 0.00 
10-mWT (s) 34 10 4.8 1.2 2.2 to 0.1 13% 0.03 
10-mWT 2nd 
Trial 29 8.8 1.9 0.7 1.1 to 0.2 8% 0.00 
10-mWT 3rd 
Trial 10 7.8 1.1 0.9 1.6 to 0.1 11% 0.04 
Average 10-
mWT 34 10.2 4.8 1.4 2.4 to 0.3 16% 0.01 
Best 10-
mWT 34 9.8 4.8 1.4 2.5 to 0.3 15% 0.01 
Worst 10-
mWT 34 10.3 4.7 1.3 2.3 to 0.3 14% 0.02 
10-mW/RT 
(s) 31 6.3 4.4 1.0 1.9 to 0.2 20% 0.02 
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10-mW/RT 
2nd Trial 25 4.8 2 0.6 1.0 to 0.1 13% 0.02 
10-mW/RT 
3rd Trial 9 3.7 1.5 0.3 1.3 to 0.7 8% ns 
Average 10-
mW/RT 31 6.1 4.4 1.0 1.9 to 0.1 21% 0.02 
Best 10-
mW/RT 31 5.9 4.4 1.1 2.0 to 0.1 22% 0.03 
Worst 10-
mW/RT 31 6.3 3.4 1.1 1.9 to 0.2 21% 0.03 
30SSS 
(times) 34 8.9 7.2 -1.4 -0.1 to -2.7 -13% 0.03 
30SSS 2nd 
Trial 22 13.1 6.3 -1.0 0.2 to -2.1 -7% ns 
30SSS 3rd 
Trial 6 15.7 3.1 -1.0 1.1 to -3.1 -6% ns 
Average 
30SSS 34 9.2 7.3 -1.8 -0.7 to -2.9 -16% 0.003 
Best 30SSS 34 10.1 7.3 -2.4 -1.1 to -3.7 -19% 0.00 
Worst 
30SSS 34 8.9 7 -1.3 -.15 to -2.4 -13% 0.03 
Total stands 
30SSS 34 20.2 18.8 -7.1 -3.2 to -11 -26% 0.001 
SARA: severity of ataxia rating scale, QMT: quantitative muscle test, 6MWT: 
six-minutes walking test, 10-mWT: ten meter walk test (comfortable speed), 
10-mW/RT: ten meter walk/run test (as fast as possible), 30SSS: 30 
seconds sit and stand test, N= sample size per outcome measure, SD: 
standard deviation, Mean change: mean change from corresponding 
baseline values, 95%CI: 95 percent confidence intervals around the 
estimated mean change, % from baseline: mean change/baseline value * 
100, ns: not significant. 
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3.4. DISCUSSION 
 
Assessing functionality in people with DM1 is essential to monitor natural disease 
progression and the possible effect of any intervention. The OMMYD consortium 
suggests five functional outcome measures (FOM) considered suitable for DM1. 5 
This study explores the feasibility, reliability and validity of three of these 
outcomes: the 10-mWT; the 10-mW/RT; and the 30SSS. The 6MWT has been 
explored before (39) so, for this case study, it is presented as a reference; finally, 
the Nine-hole Peg test (9HPT) has been included as an outcome measure in 
PHENO-DM1 study also, however the exploration of upper extremity outcomes 10 
has been planned as an independent project.  
 
By the time of this study, few differences on the FOM operational methodology 
and the last version of the FOM standard operational procedures (SOP) agreed 
by the OMMYD consortium were identified; these variants were: [1] two trials of 15 
the 6MWT if possible instead of one; [2] to keep the 30 meters length corridor for 
the 6MWT if possible instead of 25 m; and, [3] a firm start for the 10-mWT instead 
of a flying start. Still we do not expect these variants to impact significantly on the 
comparability of these results neither to interfere on the study conclusions. The 
findings of thesis will be presented to the OMMYD consortium for consideration 20 
before final OMMYD SOPs get submitted for publication. 
 
FOM validity and reliability: 
This study provides a cross-sectional analysis of FOM in DM1 and validates their 
use in this population, proving them to be feasible, reliable and sensitive to 25 
change. This sample size and severity distribution allows for an extrapolation of 
results when comparing to other studies and reliable estimates (100). The cohort 
included participants with a wide spectrum of disease burden including 
wheelchair users and with MIRS from I to V. However, not all the participants 
were able to complete all the assessments three times as expected. 30 
 
Significant differences exist between sexes as expected from a healthy 
population with men scoring better than women (83, 101, 102), as also shown in 
other progressive neurological disorders (103). This correlates with the 
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differences in lower limb muscle strength plus it is known that the step length of 
men tends to be longer so influencing the walking-test scores (104, 105). 
Correcting for height could reduce the level of difference in walking tests between 
the sexes; however, one aim of this study is to present reference values of a 
representative DM1 sample including categorization in the sexes with their natural 5 
characteristics (106). These differences do not necessarily indicate a more 
severe phenotype in women. In fact, in DM1 it has been reported that men more 
frequently than women have muscular weakness and disability (107). In this 
particular sample if we consider the SARA test and the MIRS classification as 
disease-severity parameters, the disease-severity distribution between the sexes 10 
shows no difference.  
 
Mean values are comparable to other relevant physically impaired disorders (84, 
108). However due to the possible variability in methodologies, cautious 
comparison should be made. The healthy reference values most commonly used 15 
for the ten meter walk test (10-mWT) and the ten meter walk/run test (10-mW/RT) 
are those established by Bohannon et al. in 1997; however, their estimations 
come from a 7.62 m timed length as the acceleration and deceleration phases 
were included in the 10-metre-length corridor (109). Hence, our results (10-mWT 
1.4 m/s (SD3.8) and 10-mW/RT 2.5 m/s to 2.6 (SD5.4)) should not erroneously 20 
be compared to a healthy population in their 40s and 50s. They perform better 
compared to the ones published by Hammaren et al. from a DM1 sample of 10 
participants (10-mWT = 10.2 (SD1.7), range 6.2-12.3 and 10-mW/RT= 7.7 
(SD1.6), range 4.7-9.8) (44). We explored the relationship between participants’ 
scores in these two tests and their perceived capability in running as scored in the 25 
DM1-ActvC questionnaire (Figure 3. 1). These interesting results suggest that, as 
a group, participants can distinguish and report their capability to perform a fast 
pace test. For this study, participants completed the DM1-ActivC before 
performing the FOM. However, the DM1-ActivC questionnaire has been 
questioned as the responses can be influenced by the participants’ daily life 30 
challenges or experiences, more than a real capacity. Certainly, the scoring of 
activities such as vacuuming and running might be influenced by the participant’s 
own experience or real need to perform them as a daily life task. It will be 
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interesting to ask participants to repeat the questionnaire after performing the 
tests and assess any impact of their recent experience of being challenged to run 
or walk as fast as possible. 
 
Normative data for the 30 seconds sit and stand test (30SSS) for a population 5 
between 20 to 80 years old range from 13 to 15 for women and from 14 to 17 in 
men (82, 110). In our population only participants performing the third trial 
accomplished these scores as a group. The averages presented on the first trial 
will be below the cut-off values predicted for a population between 60 and 70 
years old (110, 111). Variations of this test (e.g. 5 times sit-to-stand, or time-up-10 
and-go) have also good normative data for reference and good reliability; 
however, this does not allow a flooring effect and would have excluded all our 
participants not capable of standing up from the chair as required in these tests, 
with the 30SSS allowing a score of ‘zero’ for these cases and increasing the 
chances to quantify disease progression. 15 
 
The correlation scores prove once more the influence of muscle strength and 
balance (SARA) on the ability to walk and to stand up from a chair in DM1 (39, 
44, 45, 112, 113). The two walking tests (i.e. 6MWT and 10-mWT) maintain 
similar correlation trends among all tests. By showing similar correlation scores to 20 
those from the 6MWT, these tests have shown the same level of strength when 
assessing strength and disease severity as measured by SARA and PRO. Once 
more, knee extensors and ankle dorsiflexors strength have shown significant 
impact on test performance (44, 45).The correlation levels between the FOM and 
the mobility (MDHI subscale), ability to perform activities (MDHI subscale) and 25 
daily life activities participation (DM1-ActivC) scores corroborate that these FOM 
measures participants reported daily life performance and disease severity 
(overall MDHI). Interestingly the 10-mW/RT was not the FOM with the highest 
correlation values when is expected to be the most challenging test of the four, 
however this might be associated to the fact that a number of severe participants 30 
did not perform the test. Another explanation could be the measurement precision 
accomplished by each test.  Still, the correlation values are moderate or strong for 
all FOM. This is the first time that the MDHI and DM1-ActivC questionnaires are 
tested against relevant tests of functionality. Associating physiological changes 
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with health-related quality of life enriches the evidence base complementing an 
outcome as a tool to assess meaningful interventions (114). 
 
Grip strength is an outcome measure in DM1 with proven reliability and 
responsiveness, and has been suggested as disease severity surrogate marker 5 
capable of detecting real disease progression over time (27, 28, 115-118). In this 
study, associations to grip strength are presented as additional correlation test to 
an outcome representing disease progression but with no expected associated 
causality to the outcome measures (i.e. grip strength measures hand-muscle 
strength and is not expected to impact on the performance of the FOM). 10 
 
The 30SSS ICC values were higher than previous reliability reports (from 
ICC=0.84 to ICC=0.92) (119, 120). For the 10-mWT and the 10-mW/RT there 
was a high relative reliability demonstrated with ICC values comparable to or 
surpassing what has been shown in DM1 in previous studies and in other 15 
neurological disorders (44, 121-123). Still, the variability between study 
methodologies when conducting these tests has been highlighted before so 
enhancing the need for uniformity in the protocols to allow validity comparability of 
data (124, 125). Due to the sample size involved in this study and the difficulty of 
collecting this amount of data with a standardized methodology in this population, 20 
it is recommended to consider using the same methodology for the 10-mWT and 
10-mW/RT for any future clinical trial in DM1. 
 
Sensitivity and specificity: 
The ROC curve analysis showed fair and good levels when discriminating 25 
between participants according to outcomes representing participants with a more 
severe phenotype. The reasoning behind the selected outputs to compare to 
were: [1] a MIRS score of IV implies mild proximal weakness and a MIRS of V 
implies a severe proximal weakness, and it has been suggested that DM1 
patients with MIRS ≥ IV are more likely to fall and have less balance confidence 30 
than those with MIRS ≤ III (43); and [2] a SARA score of 8 has been 
demonstrated as a good predictor of a patient’s need for a walking-device  and 
that those patients with scores ≥8 and no walking-device have a higher risk of 
severe falls (42). It is not suggested that these FOM are good predictors of falls: 
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for this conclusion to be valid it will require a direct correlation to falls history or 
observed falls. However, these outputs (i.e. SARA and MIRS) were selected as 
evidence-based reference cut-offs to identify more severe participants and with 
associated issues such as falling and ability to walk independently that can 
impact on daily life activities and the quality of life (43, 45, 126). Ambulation ability 5 
predicted by gait speed has shown to be a reliable method in other neurological 
population (127, 128). 
 
Variability between tests: 
When performed more than once, the 10-mWT and the 10-mW/RT showed good 10 
test-test reliability. When testing with functional outcomes, the need for at least 
one practice trial before establishing the most appropriate results for analysis has 
been previously reported not only in healthy populations but also in DM1 and 
other diseases with motor impairment and fatigue (39, 129-134). 
 15 
In the particular case of DM1, not only the well-known learning effect is visible but 
also the possible combination with the natural lack of motivation predominantly 
present in these patients (135). Similar findings by Kierkegaard et al. for the 
following FOM: 6MWT, a variant of the 10-mWT, the timed-stands test (TST) and 
the time up-and-go (TUG) test where at least half of the participants performed 20 
their best test at either the second or the third trial. Due to the high level of 
agreement between the second and the third trial observed for the 10-mWT and 
the 10-mW/RT it is valid to assume that two trials of these tests will be enough to 
provide a valid and reliable score. Kierkegaard et al. suggested that there might 
be no need of repeated trials in the 10-mWT but that there is for additional tests 25 
such as the 6MWT, TUG and TST; with their results the question remains 
whether it would be better to report the first, the best or the average of all 
performed (129). In this study we have attempted to respond to this question as 
explained in the following sections. 
 30 
This study section also provides information about the feasibility of performing all 
these tests three times plus the 6MWT once. It is fair to say that it is feasible to 
perform these three tests at least once as even after performing the 6MWT ≥96% 
completed all three. However, due to disease-associated limiting factors such as 
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fatigue, pain and poor balance an overlong examination of these patients is 
discouraged and a careful consideration for reducing the number of assessments 
or visit length is recommended. The 10-mWT and the 10-mW/RT had a good 
retention rate with ≥95% of performers having completed it by the second trial. 
Between the first two trials of these tests we also allow ≥80% of the participants 5 
to perform their best attempt. Due to the reduced variability of these two tests 
between the second and third trials this all adds evidence for the proposal of 
performing these tests only twice. The 30SSS had a lower retention rate; 
however, the more trials were requested the more chance participants had to 
perform their best trial; this correlated to the MIRS level. These findings could 10 
justify the attempt to perform the 30SSS test three times as long as the 
participant is willing to continue and the examiner considers it safe to continue. In 
this study the participants were always asked how they felt to continue and/or if 
they felt they could do a better trial; this allowed participants to continue and self-
challenge to perform their best whenever possible. 15 
 
Timed ten-meter walking tests and sit-and-stand task assessments have been 
correlated to balance gold standard scales (i.e. Berg Balance Scale) in DM1 and 
other neuromuscular disorders (44, 136, 137). In fact, the 10-mWT and the 
30SSS have been recommended to supplement the ceiling effect commonly 20 
observed on the Berg Balance Scale when assessing walking ability affected by 
impaired balance (137). The 30SSS test has previously been correlated to fatigue 
(110, 138). In this study, fatigue impact can be suggested by the reduced 
compliance from trial to trial associated to participants’ reported fatigue and by 
the moderate and strong correlation shown with the MDHI-fatigue subscale (table 25 
3.4). Finally, 30SSS can be significantly influenced by the level of cognitive 
functioning (139). The possibility to assess other symptoms related to DM1 
disease burden such as balance, fatigue or cognitive impairment could be seen 
as strength for interventions expecting a multisystem effect. 
 30 
The results of the SEM (SEM%) estimations were: [1] 0.53 sec (5%) for the 10-
mWT; [2] 0.44 sec (8%) for the 10-mW/RT; and [3] 1.4 times (10%) for the 
30SSS. The 10-mWT and 10-mW/RT SEM% values are similar to those 
established by Flansbjer et al. for a post-stroke population of a mean age of 58 
 54 
 
(SD6.4) years old with a 5.7% and 7.9% estimated change for each test (140). A 
SEM score for the 10-mWT and the 10-mW/RT was reported before for a sample 
of 10 DM1 patients, with an estimated SEM of 0.6 and 0.4, respectively (44). And 
the 30SSS are close to those established for patients with hip osteoarthritis (1.27 
times) (79). 5 
 
Longitudinal analysis: 
The last section of the study aimed to document the progression of the disease 
as assessed by changes in strength and FOM. When analysing responsiveness 
to natural disease progression, the mean change after 12 months from baseline 10 
indicates a clinically relevant disease progression as measured by the 
progression detected in all FOM (6MWT included), the SARA as a disease 
severity parameter and knee extensor’s strength, and a muscle group with the 
highest intra-rater QMT consistency. All FOM had at least three scores 
significantly higher than the SEM% which validates this change as real clinical 15 
change at group level. This compares to a longitudinal analysis testing upper limb 
performance test that only detect significant change in two of the four tools tested 
after nine years of follow-up (118). The scores with the highest change in 
percentage (%) from baseline can be suggested as the best score to report 
and/or include for analysis. The 10-mWT and 10-mW/RT had very similar results 20 
when considering the average of the performed trials or when considering only 
the best or the worst one. The 30SSS, on the other hand, showed a significantly 
higher sensitivity to change when the total stands achieved or the best trial score 
are considered. This adds up to the proposed encouragement for three trials in 
the 30SSS to elicit the participants’ best score.  25 
 
Based on the results of this study, preliminary estimates and power calculations 
for a randomised controlled clinical trial and a one arm observational study using 
these outcome measures as primary endpoint can be calculated. For a two-arm 
study, a sample size of at least 65 participants per group would be required to 30 
allow the detection of a 20% difference or change in the FOM performance with 
90% power (99, 141). For a one-arm study, a cohort of 40 patients is enough. 
This assumes that patient populations are similar to this study, and that the 
variations of FOM values are not higher. Both the Optimistic and the PhenoDM1 
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studies have recruited more participants per study arm, so would be likely to 
generate statistically significant results. However an important point to analyse in 
the future is how much change is really needed for it to be considered a relevant 
change for the patient. In this case we estimated for a 20% difference between 
groups or change in time to allow at least a change of two times the expected 5 
SEM% for each FOM. These findings are just estimates and will need further 
investigation as every trial has unique characteristics to be added to the 
estimations.  
 
Limitations from this study are: [1] these assessments were part of a day-long 10 
study visit, which may have contributed to fatigue; [2] each examiner might have 
different criteria when deciding to stop a test, which have not been accounted for 
as a reason for discontinuing the trials; [3] the reduced sample at follow-up in 
comparison to the baseline sample size. The final analysis including the whole 
sample at follow-up and will compensate for some of these limitations. This would 15 
reduce intra-examiner’ variability and might identify significant correlations to 
other variables not considered at this stage.  The difference in progression 
between the mild (or late-onset) and the classic (or adult-onset) phenotypes has 
been detected before and there is an encouragement to compare progression 
with these phenotypes as independent subgroups but for this, we would need the 20 
bigger sample. 
 
3.5. CONCLUSIONS 
 
Based on a systematic review published in 2017 about muscle and performance-25 
based assessment instruments in DM1 this is the first time that a full analysis of 
reliability, validity and responsiveness has been made for the 10-mWT, the 10-
mW/RT and the 30 SSS(142). 
 
Overall, this study has defined a baseline and twelve-month follow-up reference 30 
suitable for future studies interested in assessing functionality in DM1. It has 
identified possible limitations of the assessments like the variability between each 
subject’s ability to complete the full set of assessments when part of a long and 
complex study visit. 
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It is recommended to follow this study’s methodology when considering any of 
these FOM for clinical research to allow an appropriate comparison for these 
reference values. When performing the 10-mWT and 10-mW/RT it is suggested 
to perform two trials and record the best score or the average of the two trials. For 5 
the 30SSS the attempt of three trials is encouraged, giving a chance for the best 
performance to occur at any of the attempts and report the score of the best 
performance. 
 
For interventions offering improvement in DM1 patients’ functionality and/or 10 
strength, it is encouraged to perform these three tests together. Even though they 
all assess strength and disease severity, they seem to complement each other as 
30SSS most probable provides more information about balance and fatigue to the 
table, whereas the other two tests (10-mWt and 10-mW/RT) directly assess the 
capability and confidence to walk, and walk or run at maximal speed. This FOM 15 
battery may make the 6MWT redundant in order to assess strength, walking 
capability and disease severity; plus, the feasibility of performing the 10-mWT for 
more than one trial is better than performing more than one trial of the 6MWT. 
 
A cohort of 34 DM1 participants has shown a significant increase in disease 20 
severity and decline in FOM scores above the minimum expected which should 
be considered as real change and not an error in the measurement. However, to 
better understand the progression of the disease functional-impairment with these 
FOM, further studies need to evaluate the natural FOM progression as whole 
cohort and in the mild and classic phenotypes as independent subgroups. Also, 25 
the use of repeated measures with more than two follow-up visits in the 
observational study would enrich final conclusions. 
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CHAPTER 4. EXPLORING WEARABLE ACCELEROMETRY-BASED ACTIVITY 
MONITORS IN MYTONIC DYSTOPHY TYPE 1 
 
4.1. INTRODUCTION 
 5 
Over the last decades, new technology has been refined to monitor activity of 
daily living with potential use in research and health-care practice for a variety of 
diseases including neuromuscular disorders (143, 144). Habitual physical activity 
(HPA) refers to any activity performed in the natural environment and it measures 
someone’s participation and functionality in daily life (19, 145). One of the most 10 
advanced ways for assessing HPA levels is by quantifying objectively the body 
acceleration when moving (accelerometry). Hence, accelerometers have been 
used to estimate functioning, disability and health by assessing movement quality 
and movement persistence in daily life activity (52, 146, 147). However the 
understanding of these tools’ applicability in diseases like DM1 is in its early 15 
stages and there is still work to do before presuming validity and reliability for any 
clinical trial. 
 
The aim of this study was to explore wearable accelerometry-based technology in 
Myotonic Dystrophy type 1 (DM1) to assess habitual physical activity patterns. It 20 
will do so by addressing the following questions: (1) Part I: What sorts of activity 
monitor devices have been used previously to measure HPA in DM1 and similar 
neuromuscular disorders; and: Which methodology have these studies followed; 
(2) Part II: Is it valid to assess ambulation and other functional activities in DM1 
with accelerometry; and: Is there a location on the body for these devices to 25 
assess walking activities in DM1 better; and (3) Part III: What would an 
accelerometry-based device tell us about the HPA patterns in the fatigued DM1; 
How does it differ from other fatigued cohorts and from the non-affected by DM1; 
and: Does HPA in DM1 change over time? 
 30 
4.2. METHODS 
 
4.2.1. Part I: Systematic Review [Appendix B] 
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Aiming to identify previously used activity monitors and assessment 
methodologies in DM1, a systematic review was performed by searching for any 
published study reporting the use of an activity monitor assessing HPA in 
neuromuscular disorders (148). For the purposes of the publication, patient-
reported outcomes, assessing HPA in neuromuscular disorders, were also 5 
included; however, for this thesis, only the search part related to activity monitors 
will be presented. 
 
Search Methodology 
An initial literature search was performed through the electronic databases: 10 
EMBASE, MEDLINE and PsychINFO including the terms “physical activity”, “free 
living activity” and “daily life activity” in combination with “neuromuscular 
disease(s)”, “neuromuscular disorder(s)”, “muscular dystrophy” and “muscle 
disease(s)”. The initial search was performed and the following selection process 
followed a systematic search methodology. The titles and abstracts of all 15 
retrieved references were screened excluding. All papers that did not fulfil the 
inclusion criteria or had an evident exclusion criterion were excluded. Publications 
selected as possible for reporting the use of HPA measures in NMD were proof 
reviewed by two other independent researchers (SC and JN) and only those with 
common consensus were included for analysis. 20 
 
Inclusion and Exclusion Criteria 
The search included publications between 1996 and March 2016 (time of the 
literature search).  
 25 
Papers included for analysis fulfilled the following criteria: (1) including 
participants with a progressive neuromuscular disorder; and (2) meeting the 
definition of habitual physical activity as in daily life (145, 149). Publications were 
excluded when: (1) not published in English; or (2) single cases, reviews, 
conference abstracts or pre-clinical studies. 30 
 
Data extraction  
At first, a selection of papers fulfilling the inclusion criteria was made and papers 
were evaluated independently with the collaboration of two independent 
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reviewers (SC and JN) identifying the following study variables: (1) sample size 
and age distribution; (2) study design and follow-up duration; (3) study aim; (4) 
study primary outcome; and (5) any HPA-related results reported. If any 
information was not reported or specified it was recorded as not available.   
 5 
4.2.2. Part II: Validity of an accelerometry-based device and site of placement in 
DM1, a cross-sectional study. 
 
When performing the systematic review two studies were identified as ongoing at 
that time but using accelerometry-based activity monitors in DM1. One of these 10 
was the OPTIMISTIC study (NCT02118779), which used an ankle-worn 
accelerometer (GENEActiv) for two weeks after each study visit (150, 151). To 
test the concept of using GENEActiv devices with DM1 patients, this study 
explored the use of GENEActiv on the ankle as against the wrist in a DM1 group 
and compared it to a healthy cohort.  15 
 
The study was covered under the ethical approval of the PHENO-DM1 study 
(NCT02831504) by The Newcastle and North Tyneside Ethics committee (Re: 
NE/15/0178). 
 20 
Sample 
Participants were recruited as part of the ongoing DM1 natural history study, 
PHENO-DM1. This cohort includes 30 patients recruited to one of the sites (Royal 
Victoria Infirmary - Newcastle Upon Tyne NHS Foundation Trust) and assessed 
at baseline. Selected participants were all genetically confirmed DM1 adults able 25 
to consent and to perform the functional assessments independently. Walking 
assistive devices and orthosis were permitted. Patients were classified as mild if 
they met two of the three following criteria: 1) First symptoms reported at the age 
of 40 or older; 2) 200 or fewer CTG repeats as mutation length; and 3) a score of 
1 or 2 on the Muscular Impairment Rating Scale (MIRS). This DM1 cohort was 30 
compared against a healthy-control group formed by adult volunteers from 
Newcastle University (students and staff). The collection of data from the healthy 
volunteers was covered under internal ethical approval of the university.  
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Study assessments 
All participants wore four accelerometers at the same time: one on each limb 
(right wrist, right ankle, left wrist and left ankle) while performing different 5 
functional tasks. Functional assessments performed were performed in the 
following order: (1) stand still for a minimum of ten seconds; (2) six minutes 
walking test (6MWT); (3) ten meters walking test (10-mWT); and (4) ten meters 
walk/run test (10-W/RT). The aim of these ordered study assessments were to 
obtain accelerometry data representative of different walking paces. The protocol 10 
for these tests has been described in the previous chapter.  
 
The following time points were recorded: (1) time when devices were placed on; 
(2) time participant started to perform each task; (3) time participant stopped 
performing any task; (4) resting periods, either sitting or standing; and (5) time 15 
when devices were taken off. 
 
GENEActiv 
The GENEActiv (Activinsights Ltd., Cambridgeshire, UK) is a tri-axial, ±6 g 
seismic acceleration sensor. It is portable device that measures 36 20 
cm × 30 cm × 12 cm and weights 16 g. GENEActiv offers a near 
body temperature and light sensor to allow identification of wear 
and non-wear time. Wrist-worn GENEActiv has demonstrated 
strong validity against indirect calorimetry for both physical activity 
and sedentary behaviour (152, 153). 25 
 
The unit of measurement presented is the Euclidean Norm Minus One (ENMO – 
mg), which not only considers the raw data of the three planes of acceleration 
provided by the device but also systematically includes gravity into its algorithm 
(as in (x2 + y2 + z2) 1/2 – 1) making it more reliable for dynamic physical activity 30 
estimations (150, 154, 155). 
 
GENEActiv devices were configured to their maximum sampling frequency of 100 
Hz. Downloaded (.bin files) were converted to 1s epochs and imported into a 
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custom-built Excel spreadsheet. Based on the assessor records, start and finish 
time for each of the functional tasks and the closest 10 seconds were plotted to 
identify the real start point as the point with a visible increment in value and 
continued until the recorded finish time. For each functional task’s set of data, the 
mean value per second was calculated and then multiplied by 60 to obtain a 5 
value per minute for each task (156). 
 
Statistics 
Normality distribution was tested for each individual set of data with the Shapiro-
Wilk test. Intraclass Correlation Coefficients (ICC) estimates and their 95% 10 
confident intervals were calculated based on a mean-rating absolute-agreement, 
2-way random model to measure reliability within each accelerometer and 
between accelerometers (62). ICC measures the degree of correlation and the 
agreement between measurements provided by the device. Pearson correlation 
coefficients (r) are also reported for each functional test comparing an all-seconds 15 
sequence along the test. Bland-Altman plots were used to examine the 
agreement level between ankle measurements and wrist measurements for each 
functional task (64, 157). Sex (male/female) and age (years) were tested on an 
adjusted model as possible confounders as these factors were different between 
groups and might impact on the outcomes tested.  20 
 
All statistical analyses were performed using SPSS version 23 (IBM Corporation, 
SPSS Inc, Chicago, IL) and only results with p-values ≤0.05 have been described 
as statistically significant.  
 25 
4.2.3. Part III: Habitual Physical Activity in DM1, a longitudinal study. 
 
This part of the study aimed to test the feasibility of the OPTIMISTIC protocol: an 
ankle worn GENEActiv to quantify habitual physical activity (HPA) levels in 
fatigued DM1 adults. This study has two parts: (1) a cross-sectional study 30 
comparing HPA patterns from a fatigued DM1 group against a healthy-volunteers 
group and a chronic fatigued group (CFS); and (2) a 16-month follow-up of the 
same DM1 group.  
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This study is covered under the ethical approval of the OPTIMISTIC trial 
approved by The Newcastle and North Tyneside Ethics committee 
(Re:13/NE/0342). 
 
Sample 5 
The fatigued DM1 cohort was recruited to the OPTIMISTIC multicentre study and 
these are participants from two of the four centres (Newcastle and Nijmegen). 
The OPTIMISTIC study is composed of four follow-up visits (including the 
baseline) and for each visit, participants will be requested to wear the GENEActiv 
device for 14 consecutive days, 7 of which will be selected for analysis (69). The 10 
healthy cohort corresponds to the same cohort used for the GENEActiv ankle-
wrist validation study (part II). For this part, volunteers were asked to wear an 
ankle device for 7 consecutive days. Finally, the chronic-fatigued-syndrome 
(CFS) sample belongs to a population attending the Radboud University Medical 
Centre in Nijmegen, The Netherlands. CFS patients were screened along the 15 
same period of the DM1 cohort and by one of the OPTIMISTIC partners, following 
the same baseline protocol. Age, gender, BMI and fatigue severity were collected 
for each participant at baseline. Additional outcomes of disease severity were 
collected for the DM1 group at each study visit and considered for the longitudinal 
analysis. For the longitudinal analysis, the DM1 sample was subdivided into a: (1) 20 
treatment allocation group; and (2) classic and mild (or late onset) phenotype as 
explained earlier (158); allowing for exploration of any potential differences in 
these subgroups either at baseline or with time.  
 
GENEActiv 25 
HPA was measured by GENEActiv accelerometer worn on a daily basis in the 
participants’ normal environment (159).  
 
Instructions on how to use the GENEActiv were provided whenever the device 
was allocated to the participant and it was placed as applicable at the end of the 30 
visit. Participants were instructed to wear the GENEActiv monitor around the 
ankles of their non-dominant side (per-protocol) continuously for seven days (for 
the healthy cohort) and 14 days (for the DM1 cohort and the chronic fatigued 
cohort). The device is waterproof but participants were advised to take them off 
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when showering or taking a bath. Participants were expected to return the device 
by post when finished. 
 
GENEActivs were configured with a sampling frequency of 50 Hz for 15 days. In 
this case, the system Matlab (Matlab v 12.0, Mathworks, Natick, MA) was initially 5 
used to filter the information. Seven consecutive days were expected to be 
extracted from the returned device. Data were considered valid when these 
reported a wearing time of a minimum of 23 hours per day and a minimum of five 
full days had been extracted for the healthy controls and seven days for the DM1 
and the CFS groups (160). The selected unit measure was ENMO (Euclidean 10 
Norm Minus One - mg), as in (x2 + y2 + z2) 1/2 – 1), and this was summarized as 
average ENMO (mg) values over 24 hours over the 7 days, the average of the 
most active 5 hours of the 7 days (M5 ENMO) and the average of the least active 
5 hours of the 7 days (L5 ENMO) as shown in the figure (150, 151, 161).  
 15 
Measures of fatigue severity 
The Checklist of Individual Strength (CIS) is a 20-item long questionnaire that 
measures four different dimensions that impact on someone’s perceived fatigue 
levels and are factors that may influence fatigue perception. The four dimensions 
include: (1) fatigue severity; (2) concentration problems; (3) reduced motivation; 20 
and (4) reduced physical activity (162). This outcome measure has shown very 
good internal consistency and reliability and with moderate to high correlation 
strength with other known fatigue scales. When assessing fatigue severity, a cut-
off score of 35 has previously been used to distinguish those severely fatigued 
(163). All the participants of these studies completed a CIS questionnaire before 25 
wearing the accelerometer. 
 
Measures of disease severity 
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Patient-reported disease severity was considered, based on scores from two 
disease-specific questionnaires: (1) the Myotonic Dystrophy Health Index (MDHI), 
a 114-item (symptoms prevalence and life-impact) questionnaire (81); and (2) the 
DM1-ActivC scale, a 20-item Rasch-built scale that measures the patient’s 
participation in daily life activities (73). The Muscular Impairment Rating Scale 5 
(MIRS) was considered as the clinical disease severity outcome. MIRS is a 
disease-specific 5-point scale with which the clinician assesses and scores the 
weakness and impairment progression of the muscle affection (74). 
 
Statistics 10 
Descriptive statistics (mean and standard deviation [SD]) were used to describe 
the sample’s characteristics. Baseline characteristics were compared between 
groups. An intraclass correlation coefficient (ICC) was estimated for each of the 
functional test results by comparing the average acceleration value per minute of 
each accelerometer. HPA progression over time was performed by a paired t-test 15 
between each time point and baseline for each individual group (164). 
Comparison between groups was tested with a non-parametric Mann-Whitney 
test at each time point. All statistical analyses were performed using SPSS 
version 23 (IBM Corporation) and only results with p-values ≤0.05 are presented 
as statistically significant. Sex (male/female) and age (years) were tested on an 20 
adjusted model as possible confounders as these factors were different between 
groups and might impact on the outcomes tested. A percentage of the standard 
error of the mean (SEM%) was assessed as a measure of within subject’s 
deviation over seven days and it was calculated as followed: SEM%= (standard 
deviation x √(1-reliability)) x 100. The standard error of the mean was estimated 25 
from the standard mean ENMO change across seven consecutive days. This 
measurement can be used to determine the limit for the smallest change 
expected to claim a real change for a group of subjects with these characteristics 
following an intervention (165).  
 30 
4.3. RESULTS 
 
4.3.1. Part I: Systematic Review 
 
 65 
 
The literature search retrieved 1,070 published titles and abstracts matching the 
search criteria. Eighty-nine full papers were selected by the first reviewer (CJM) 
and after detailed reviews by two independent researchers (SC and JN), 22 (166-
187) were selected for analysis. Appendix B includes a summary of the protocols 
used by each of the identified papers recognized as assessing habitual physical 5 
activity in a form of neuromuscular disease. Sixteen of these studies (166, 168, 
170, 172-179, 181-184, 187) quantitatively assessed activity levels as opposed to 
qualitative assessment (i.e. patient-reported outcome). Authors of six of these 
papers were contacted to complete information regarding the methodology used. 
Of the 22 papers, only three presented a clear attempt to systematically validate 10 
their utilized tool in their populations of interest (172, 178, 184). 
 
There was only one study identified exclusive to DM1 participants; the study used 
the StepWatch activity monitor (SAM) for 7 consecutive days around the ankle 
(126), aiming to investigate the incidence of falls and stumbles in DM1. This 15 
cardinal study reported for the first time an increased falls rate in patients with 
DM1 when compared to healthy controls and that ankle strength correlates best 
with gait speed (r=0.92, p<0.001). Kalkman et al. (182) studied a large mixed 
neuromuscular diseased sample including a myotonic dystrophy group. They 
used the actometer Actilog V3.0 worn on the ankle for 12 consecutive days, 20 
showing a correlation between the actometer reports and the functional 
impairment scores obtained from the Sickness Impact Profile (SIP) questionnaire; 
however, this did not correlate with reported fatigue. 
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Figure 4. 1 Activity monitors (by models) identified in the systematic search 
 
Over the last decade, there has been a notable increase in the use of 
accelerometry-based HPA studies. At the time of this review, the most popular 5 
activity monitor used in neuromuscular diseases was the StepWatch Activity 
Monitor (SAM), reported in five out of the 16 papers followed by heart rate 
monitors (Figure 4. 1). The time period of activity monitoring ranged from two to 
twelve days with three as the most common. The protocol of ‘during waking 
hours’ was more common than the 24-hours wear-time rule (Figure 4. 2). Four 10 
studies did not provide full details of the model used or the location where the 
device was placed (168, 173, 174, 179) and the full data collection protocols (data 
criteria for analysis, definition of non-wear episode and the processing of missing 
data) were only identifiable in three of the papers (170, 172, 181). Four papers 
reported the use of a patient-reported outcome (i.e. activity diary) as a quality 15 
control method (173, 178, 179, 184). McDonald et al. was the only study 
assessing issues of feasibility, with an explanation of lost data from heart rate 
monitors due placement issues (188). 
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Figure 4. 2 Monitoring protocols reported when assessing habitual physical activity 5 
with activity monitors: monitoring periods, body location and expected wearing 
(active monitoring) time; identified in the systematic search. 
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4.3.2. Part II: Validity of an accelerometry-based device and site of placement in 
DM1, a cross-sectional study. 
 
4.3.2.1. Accelerometers’ validity 
 5 
Data from 30 DM1 participants and from 14 healthy volunteers were cleaned and 
collected. Data from 2 accelerometers from the healthy group were lost due to 
machine error. Table 4. 1 presents each group’s demographics. There was a 
significant age difference between groups. As a whole sample, with the exception 
of demographic values and the accelerometer output data from ankle-worn 10 
accelerometers during the six-minutes walking test (6MWT) and the left ankle ten-
meters walk test (10-mWT) outputs, all other accelerometer variables showed a 
not-normal distribution. When normality tests were done individually per sample, 
the healthy control group showed a normal distribution in all variables except 
three: right wrist ten-meter walk/run test (10-mW/RT) and both ankle reports 15 
when standing still. On the other hand, the DM1 group only remained normally 
distributed on the demographic variables and on the reports of the right ankle 10-
mW/RT.  
 
Table 4. 1 Characteristics of the sample groups: DM1 patients and healthy-20 
control volunteers. 
 DM1 Healthy-controls 
No. (No of males) 30  (20 m) 14 (6 m) 
Age – years (min-max) 47.8 (25-72) 32.3 (23-47)* 
Height – cm (SD) 171 (7.9) 167.7 (11.2) 
BMI (SD) 25.3 (4.8) 24.1 (3.9) 
* Difference between groups is statistically significant 
 
The mean acceleration values for each of the performed tests and the standing-
still position are presented for each group in Table 4. 2. These values come from 
the average-per-minute estimations performed for each different test. All tests 25 
showed significant differences between groups.  
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Table 4. 2 Mean acceleration values for each of the performed tests and 
standing-still position for each group. 
Test Location DM1 Healthy controls p value 
  Mean (SD) 95% CI Mean (SD) 95% CI  
6MWT Left ankle 47.6 (16.5) 41.5-53.7 74.4 (15.5) 65.1-83.8 < .001 
Right ankle 47.8 (16.6) 41.6-54 75.5 (14.4) 66.4-84.7 < .001 
Left wrist 21.3 (15.6) 15.5-27.1 40.6 (20.7) 27.5-53.7 < .001 
Right wrist 20.3 (13.8) 15.2-25.5 41.9 (24.5) 26.3-57.4 .002 
10-mWT Left ankle 37.4 (9.5) 33.8-41 46.0 (6.7) 41.8-50.2 .001 
Right ankle 37.6 (8.8) 34.2-40.9 48.1 (9.7) 41.9-54.3 .001 
Left wrist 13.2 (3.7) 11.8-14.6 17 (5.6) 13.5-20.5    .031∧ 
Right wrist 12.1 (3.2) 10.9-13.3 18.1 (8.1) 13.0-23.2 .001 
10-
mW/RT 
Left ankle 101.6 (50) 82.1-121 183.6 (36) 160.9-206 < .001 
Right ankle 98.1 (44.3) 80.9-115 176.5 (32) 155-198 < .001 
Left wrist 99.3 (14.5) 66.8-132 210.6 (35) 189.5-232 < .001 
Right wrist 94 (80.5) 62.8-125 214.9 (42) 188-241.9 < .001 
Stand 
Still 
Left ankle 1.2 (1.3) 0.7-1.7 1.9 (1.9) 0.7-3.1 ns 
Right ankle 1.3 (1.2) 0.8-1.7 1.7 (1.7) 0.6-2.7 ns 
Left wrist 2.3 (2.3) 1.5-3.2 2.7 (1.9) 1.5-4.0 ns 
Right wrist 2.3 (1.6) 1.7-3.0 2.5 (1.5) 1.4-3.4 ns 
Mean (SD) and 95% Confidence intervals of the accelerometer output (mg) recorded by 
each device during each activity performed and compared between groups. ns not 
statically significant. 6MWT (six minutes walking test), 10-mWT (10 meters walk test), 10-5 
mW/RT (10 meters walk/run test). ∧when adjusted to age and gender the significance 
level changed to .08 and estimated marginal means of 16.7 for healthy controls and 13.4 
for the DM1 group.  
Data from each joint was analysed independently to compare the differences from 
test to test. The mean differences from test (or activity) to test were all significant 10 
for all tested accelerometer placement sites. However, the distinction between the 
results from the two walking tasks 10-mWT (comfortable speed) and 6MWT (sub-
maximal speed) was clearer on the Healthy Control group with no overlap of the 
percentile estimations. When dividing DM1 into classic and mild phenotypes, the 
significance between the mean values of the healthy and the mild phenotype 15 
groups disappears. Figure 4. 3 exemplifies the 6MWT and the 10m-W/RT cases 
for each joint. On these graphs there is a clear difference between the 
acceleration levels reached by the ankle and wrist when walking (6MWT) and 
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how these change when speed is increased to running (10-mW/RT). This order 
swap between wrist and ankle was not the case on the classic phenotype; in this 
sub-group, ankles remained the fastest joint even when running. 
 
 71 
 
Figure 4.3 Bar chart with standard error bars representing the accelerometry values per minute reached on average by each joint 
and compared between the groups: 1) left side: healthy controls vs. DM1 patients; and 2) right side: healthy controls vs. DM1 patients 
subdivided into classic and late (mild) onset. Tests exemplified here correspond to the 6MWT (six minutes walking test) graphs above 
and the 10-mRT (10 meters walk/run test) on the graphs below. Values on y-axis represent the average of acceleration counts 
estimated per minute for each activity. 5 
Figure 4. 3 Bar charts: accelerometry values per minute reached on average by each joint and compared between the groups. 
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4.3.2.2. Inter-accelerometer reliability 
 
The intra-class correlation (ICC) of acceleration per second was also estimated 
from the data obtained at each second of the 6MWT and from the per-minute 5 
estimations for each one of the functional tests. ICCs ranged from .44 (6MWT at 
every second) to .97 (6MWT per minute). The lowest ICC values were for the 
6MWT per second scores and the widest 95% CI were for the activity of standing 
still (Table 4. 3).  
 10 
Table 4. 3 Intraclass Correlation Coefficient (ICC) test between accelerometers 
at each performed test. 
Activity Group ICC 95% CI 
6MWT per second 
Healthy 
Control 
0.440 0.28-0.56 
DM1 0.510 0.43-0.6 
6MWT per minute 
Healthy 
Control 
0.940 0.85-0.98 
DM1 0.972 0.95-0.99 
10-mWT 
Healthy 
Control 
0.848 0.6-0.96 
DM1 0.854 0.74-0.93 
10-mW/RT 
Healthy 
Control 
0.762 0.38-0.93 
DM1 0.960 0.93-0.98 
Standing Still 
Healthy 
Control 
0.726 0.24-0.93 
DM1 0.504 0.13-0.74 
Intraclass Correlation Coefficient (ICC) between accelerometers at each of the 
performed tests for each group. 6MWT (six minutes walking test), 10-mWT (10 
meters walk test), 10-mW/RT (10 meters walk/run test). 15 
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4.3.2.3. Inter-accelerometer (joint-placement position) reliability 
 
Table 4. 4 presents the Bland-Altman Plot estimations obtained from the 
difference in mean values of one accelerometer to another and the mean and 5 
standard error between both. One sample T-test showed significant differences (p 
<0.05) between wrist and ankle accelerometers in all tests except for running; 
these come together with a strong linear regression score. Wrist and wrist results 
for the 10-mWT were also statically significant but these do not have a significant 
coefficient of regression. Bland-Altman Plots present a Y-axis representing the 10 
difference from the mean estimated value (red line) and an X-axis with the mean 
acceleration values spread within the 95%CI (blue lines). Figure 4.4 represent 
four different Bland-Altman plots with different distributions as an example. Two of 
these compare the same test (6MWT) between wrist-wrist results and ankle-ankle 
results. And two compare wrist vs. ankle for the walking test and the walk/run 15 
results, this latter shows a better spread distribution of plots along the estimated 
mean. Table 4. 4 also presents the correlation values and significance between 
each of the accelerometer’s data.  
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Table 4. 4 Inter-accelerometer (joint placement position) reliability testing. 
                                 Bland-Altman Plot estimations                            Correlation 
Activity Joints Group Difference in 
Mean  
Sig. 95% Interval of 
agreement 
Coefficient 
of 
regression 
r Sig. 
6MWT Wrist-Ankle Healthy 
Control 
31.8  <.05 * 23.1-40.5 <0.001 0.83 <.001 
  DM1 26.3  <.05 * 23.2-29.4 <0.001 0.85 <.001 
  All 27.8  <.05 * 24.7-31.1 <0.001 0.91 <.001 
 Wrist-Wrist Healthy 
Control 
2.4  0.4 (-)16.5-21.2 ns 0.93 <.001 
  DM1 0.99  0.2 (-)7.3-9.2 ns 0.87 <.001 
  All 1.4  0.2 (-)10.5-13.2 ns 0.95 <.001 
 Ankle-Ankle Healthy 
Control 
(-)1.84  0.1 (-)9.7 - 6 ns 0.92 <.001 
  DM1 (-)0.2  0.7 (-)6-5.6 ns 0.98 <.001 
  All (-)0.67  0.2 (-)7.2-5.8 ns 0.99 <.001 
10m-WT Wrist-Ankle Healthy 
Control 
28.3 <.05 * 20.8-36.7 <0.001 0.65 <.001 
  DM1 24.2  <.05 * 10.5-37.9 <0.001 0.57 0.001 
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  All 23.4  <.05 * 12.6-38.1 <0.001 0.66 <.001 
 Wrist-Wrist Healthy 
Control 
(-)0.6  <.05 * (-)9.1-7 ns 0.79 <.05 
  DM1 (-)1.1  <.05 * (-)5.7-3.4 ns 0.67 <.001 
  All (-)0.97  <.05 * (-)6.8-4.8 ns 0.76 <.001 
 Ankle-Ankle Healthy 
Control 
(-)1.2  -0.2 (-)15.4-12 ns 0.53 ns 
  DM1 (-)0.2  0.8 (-)8-7.6 ns 0.83 <.001 
  All (-)0.46  0.6 (-)10.3-9.4 ns 0.86 <.001 
10-mW/RT Wrist-Ankle Healthy 
Control 
(-)24.6  0.06 (-)105.3-56.1 ns 0.24 ns 
  DM1 2.3  0.8 (-)81.6-86.2 ns 0.85 <.001 
  All (-)5.8  0.4 (-)91.3-79.7 ns 0.5 <.001 
 Wrist-Wrist Healthy 
Control 
(-)6.7  0.5 (-)64.6-51.2 ns 0.64 0.03 
  DM1 5.3  0.2 (-)39.7-50.2 ns 0.92 <.001 
  All 1.7  0.7 (-)48-51.3 ns 0.76 <.001 
 Ankle-Ankle Healthy 
Control 
7.5  0.3 (-)35.1-50.1 ns 0.61 ns 
  DM1 3.5  0.2 (-)22.3-29.4 ns 0.98 <.001 
  All 4.6  0.1 (-)26.1-35.2 ns 0.6 <.001 
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The first section of this table presents the Bland–Altman plot estimations assessing the level of agreement between accelerometer 
outputs (ENMO-mg) obtained from two different monitors either placed on the wrist(s) or placed on the ankle(s). *When the 
differences between the mean are statistically significant, a Bland-Altman plot is not valid as there is no agreement between these 
two sets of data. The second section of this table presents the coefficient of regression estimated between the difference between 
the means and mean estimated value, when this value is statically significant (<0.05) this indicates a distribution with a trend that 5 
does not support reliability between devices. Finally, the third section of the table presents the Spearman correlation (rho) results. 
ns = not statistically significant.
Standing 
Still 
Wrist-Ankle Healthy 
Control 
(-)1.4  <.05 * (-)5.7-2.8 ns 0.27 ns 
  DM1 (-)1.2  <.05 * (-)5.8-3.5 0.01 0.5 0.005 
  All (-)1.2 <.05 * (-)5.7-3.3 <0.001 0.2 ns 
 Wrist-Wrist Healthy 
Control 
0.3  0.99 (-)4-4.6 ns 0.55 0.09 
  DM1 (-)0.003  0.99 (-)5.3-5.3 ns 0.43 0.02 
  All 0.08  0.9 (-)4.9-5.1 0.04 0.1 ns 
 Ankle-Ankle Healthy 
Control 
0.2  0.5 (-)3.8-4.1 ns 0.07 0.8 
  DM1 (-)0.1  0.5 (-)1.5-1.3 ns 0.58 0.001 
  All (-)0.02  0.9 (-)2.4-2.3 ns 0.7 <.001 
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Bland-Altman Plot – 6MWT wrist vs wrist Bland-Altman Plot – 6MWT ankle vs ankle 
Bland-Altman Plot – 10-mWT wrist vs ankle Bland-Altman Plot – 10-mW/RT wrist vs ankle 
1.4 
13.2 
-10.5 
-0.7 
5.8 
7.2 
25.4 
28.1 
12.6 
-5.8 
-91.3 
79.7 
Figure 4. 4 Four different examples of Bland-Altman Plots. 
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Figure 4.4. Bland–Altman plots representing the agreement between accelerometer outputs (ENMO-mg) from two different 
monitors either placed on the wrist(s) or placed on the ankle(s). The red line represents the mean value obtained from the 
difference between each accelerometer’s set of data and the second one. The blue lines represent the 95% limits of agreement 
(±1.96 SD) around this difference from the mean. 1) Plots above present the results from the 6MWT plotting, with left wrist vs. right 5 
wrist on the left hand side and left ankle vs. right ankle on the right hand side; all these have an even spread within the intervals of 
agreement and with no visible linear trend. The plots of the ankle vs. ankle plot maintains a similar distribution all along the graph, 
showing no visible impact of the increment of speed detected by the accelerometers. 2) Plots below present the results from 
computing ankle vs. wrist in two different tests, the 10-mWalkT on the left hand side and the 10-mWalk/RunT on the right hand 
side; both show a visible linear trend of distribution along the graph but only the 10-mWalkT regression coefficient was statistically 10 
significant (<0.05). 
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4.3.3. Part III: Habitual Physical Activity (HPA) in DM1, a longitudinal study. 
 
4.3.3.1. Cross-sectional analysis 
 5 
Data from 91 participants, belonging to one of the three groups: healthy volunteers 
(N=19), chronic fatigue syndrome (CFS) group (N= 12) and severely fatigued DM1 
patients (N=60), were included in this analysis. Table 4. 5 presents and compares the 
three cohorts selected for HPA analysis in severely fatigued populations such as 
DM1. There was an initial 10% to 12% of data lost from the accelerometers 10 
registered for each group, either to lost data, problems when setting up the device, 
not enough monitoring time completed or devices lost/not returned; only those with 
complete information at the baseline were included for analysis. All variables except 
age had a non-normal distribution hence these were always considered for non-
parametric tests. These populations were non-matched and the DM1 cohort mean 15 
age was older than the healthy volunteers. Both fatigued populations (CFS and 
DM1-fatigued participants) differ significantly in all outcomes from the healthy 
volunteers with the exception of the average acceleration values of the least active 5 
hours of the day (L5-ENMO) and the activity spread (SD) over the first 5 consecutive 
days of monitoring. According to the CIS reported outcome, the DM1 and CFS 20 
cohorts reported significantly lower activity levels (i.e. higher scores on the reduced 
physical activity CIS subscale) than the healthy controls. The CFS cohort reported 
the highest scores (i.e. higher levels) for perceived fatigue and concentration 
disturbances. According to the accelerometer results, DM1 demonstrated the lowest 
objectively measured physical activity levels. The CFS group had an average of 25 
62(±8) counts (i.e. accelerometry counts per minute) when only considering the 
period awake, and the DM1 group had only 51(±21) counts.  
 
To confirm the reliability of the GENEActiv at daily-life bases, this was compared to a 
previously validated actometer (or accelerometer) used as a standard at the 30 
Radboud fatigue clinics when screening patients (the white actometer). Reports from 
both accelerometers (or actometers) correlated significantly with each other (Table 4. 
6). The CFS group only showed significant correlation values between the white 
 80 
 
actometer daily outputs and the reports of the most active 5 hours (M5 ENMO) from 
the black accelerometer (GENEActiv). Bland-Altman plotting was computed to 
analyse the intra-accelerometry reliability but the difference identified between the 
means was statistically significant and with a non-significant regression coefficient 
value (p = 0.084). Accelerometer reports, correlated to the CIS-reported outcomes, 5 
were estimated but due to the sample size, the significance in correlation was only 
detectable for the DM1 cohort and for the whole sample as a cohort. There was a 
strong, significant and consistent correlation between both accelerometers (black 
and white) and the CIS-reported reduced fatigue levels (Table 4. 7).  Patient-reported 
outcomes correlated significantly to the accelerometer reports of activity (except for 10 
the L5 ENMO values) with strong values (r >0.45) for the CIS-reported activity levels 
and the MIRS and DM1-ActivC disease severity outcomes (Table 4. 8).   
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Table 4. 5 Cross-sectional study sample demographics presenting objectively measured activity levels (accelerometer reports) and the patient-reported 
outcome Checklist of Individual Strength (CIS) results. 
  Healthy Controls CFS DM1 
Sample (N) 19   12    60  
   
Gender (% males) 37%   42% 
    
62%       
Variable mean (SD) 95% CI mean (SD) 95% CI 
sig. vs 
Healthy 
mean (SD) 95% CI 
sig. vs 
Healthy 
sig. vs 
CFS 
Age 34.5 (10.7) 29.4-39.7 42.2 (13) 33.9-50.5 ns 47.3 (10.3) 44.6-49.9 <0.001 ns 
CIS-perceived fatigue  20.4 (7.4) 16.8-24 51.4 (30.1) 49.5-53.4 <0.001 43.9 (6.2) 42.3-45.6 <0.001 <0.001 
CIS-concentration problems 11.6 (6.1) 8.7-14.5 30.8 (6.6) 26.6-34 <0.001 18.6 (7.3) 16.7-20.5 <0.001 <0.001 
CIS-reduced motivation 9.4 (3.2) 7.8-10.9 18 (5.1) 14.8-21.2 <0.001 17.9 (4.6) 16.7-19.1 <0.001 ns 
CIS-reduced physical activity 9.4 (4.9) 7-11.7 15.7 (3.5) 13.4-17.9 <0.001 16.9 (4.6) 15.7-18.1 <0.001 ns 
Overall PA levels measured by 
ActivLog (Counts over 24 
hours) 
N/A 180.6 (35.9) 157.8-203.4 N/A 138.5 (56.1)  
111.5-
165.5 
N/A ns∧ 
Overall PA levels measured by 
GENEActiv (ENMO over 24 
hours) 
44.8 (12.7) 38.7-51 28.5 (8.3) 23.2-33.7 <0.001 20.9 (11.5) 12-23.9 <0.000 0.03 
Most active 5 hours of the day 
(GENEActiv - ENMO) 
118.1 (37) 
100.2-
135.9 
61.5 (18.2) 50-73.1 <0.001 53.5 (34.8) 44.5-62.5 <0.001 0.02 
Least active 5 hours of the day 
(GENEActiv - ENMO) 
4 (1.6) 3.3-4.8 4.2 (2) 2.8-5.7 ns 4 (1.1) 3.7-4.3 ns ns 
SD over 5 consecutive days 7.8 (8.8) 3.3-12.3 7.5 (3.5) 5.3-9.7 ns 8.7 (9.6) 6.1-11.1 ns ns 
 
Demographics of the three groups involved in the cross sectional study. CFS = Chronic Fatigue Syndrome; DM1 = myotonic dystrophy 1; CIS = Checklist of Individual 
Strength; PA = physical activity; ENMO = the Euclidean Norm Minus One (mg). ∧when corrected to age significance value changed to a borderline significant 0.052 5 
and estimated marginal means of 178.4 for the CFS group and 139.5 for the DM1 group.
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Table 4. 6 Comparison between two different accelerometer models. 
  
GENEActiv (black accelerometer)   
 ENMO 24hrs M5 ENMO 
Group 
  
Spearman's r 
rho Sig. 
Spearman's r 
rho Sig. 
ActivLog 
(white 
acceleromete
r) 
ns 0.83 0.001 CFS 
0.9 <0.001 0.97 <0.001 DM1 
0.83 <0.001 0.84 <0.001 
Whole 
Sample 
ENMO: Euclidean norm minus one, M5 ENMO: most active five hours of the 
day, CFS: chronic fatigue syndrome, DM1: Myotonic Dystrophy type 1.  
 
Table 4. 7 Correlation values between objectively measured activity levels (accelerometer 
reports) and the patient-reported outcome Checklist of Individual Strength (CIS). 5 
 
HPA levels 
measured 
with 
ActivLog 
HPA levels 
measured 
with 
GENEActiv  
M5 ENMO  
  
Checklist Individual Scale (CIS)  Spearman’s r rho 
DM1 
CIS – perceived fatigue severity 
score 
ns (-)0.28* (-)0.3* 
CIS – concentration problems score ns 0.36* 0.31* 
CIS – reduced motivation score ns (-)0.36* (-)0.34** 
CIS – reduced physical activity score (-)0.58** (-)0.55*** (-)0.56*** 
WHOLE 
SAMPLE 
CIS – perceived fatigue severity 
score 
ns (-)0.49*** (-)0.53*** 
CIS – concentration problems score 0.41* ns ns 
CIS – reduced motivation score 
 
 
ns 
 
 
(-)0.54*** 
 
 
(-)0.54*** 
CIS – reduced physical activity score (-)9.45* (-)0.64*** (-)0.64*** 
CIS: checklist of individual strength questionnaire (presented by domains), HPA: 
habitual physical activity, ENMO: Euclidean norm minus one, M5 ENMO: most active 
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5 hours of the day (average over seven days). *sig.≤ 0.05   ** sig.≤0.01   ***sig.≤0.001  
ns: not-statistical significant. 
 
4.3.3.2. Longitudinal analysis 
 
Sixty severely fatigued DM1 patients during follow-up examinations were 
included in this analysis, 56 completed the first 10 months of the overall study 5 
which represents the active phase of the study and 51 completed the whole 
study. Age was the only variable normally distributed. Thirty-three participants of 
this sample (66%) belong to the group allocated to receive cognitive-based 
therapy (CBT) as part of the overall study they belong to (OPTIMISTIC study). 
Hence, all estimations were done for the whole sample as one cohort and 10 
divided, based on the allocated study arm. Sample demographics in detail are 
presented Table 4. 9. The average of the five least active hours of each day (L5 
ENMO) was the only variable differing between groups at the baseline.  
 
When analysed over time CIS-perceived fatigue showed an improvement in both 15 
groups at month 10 and month 16 after randomization, but with a larger change 
in the CBT group and when samples were compared with each other the mean 
was significantly higher in the CBT group at each follow-up visit. The CBT group 
showed a consistently significant change in other reported outcomes such as the 
MDHI score and CIS – motivation and activity level scores. Accelerometry 20 
reports showed a significant difference between groups in habitual physical 
activity (HPA) levels (22.6±8.6 vs. 15±5.1) and on the M5 ENMO (61.1±27.1 vs. 
37.6±15.1) 10 months after randomization, which represents the end of the 
active intervention. However, these values do not differ significantly from the 
baseline for either of the groups (Table 4. 10).  25 
 
Classic and mild phenotypes as defined previously in methodology were 
analysed as subgroups showing a constant difference between groups at each 
time point, with the exception of the M5 ENMO value at 10 months after 
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randomization. There were no significant changes between the baseline and any 
of the follow-ups in either of the groups (Table 4. 11).  
 
Based on the standard deviation detected per participant over the data obtained 
per day for seven consecutive days, SEM and SEM% were estimated. The SEM 5 
(and SEM%) estimated for the average HPA values were 2.7 (ENMO-mg) or 
13% of the overall HPA and 8.4 (ENMO-mg) or 17% of the most active five hours 
of the day (M5 ENMO). 
  
Table 4. 8 Correlation values between objectively measured activity levels 10 
(accelerometer reports) and outcomes of disease-severity. 
Disease Severity Scale HPA levels M5 ENMO L5 ENMO 
DM1-ActivC 0.49** 0.52** ns 
MDHI (-)0.43** (-)0.42** ns 
MIRS (-)0.51** (-)0.47** ns 
CIS – perceived fatigue (-)0.28* (-)0.3* ns 
CIS – concentration 
problems 0.36** 0.31* ns 
CIS – reduced 
motivation (-)0.36** (-)0.34** ns 
CIS – reduced physical 
activity (-)0.55** (-)0.56** ns 
* p < 0.05   /  ** p <0.01   /  ns not-significant 
MDHI Myotonic Dystrophy Health Index / MIRS Muscular 
Impairment Rating Scale / CIS Checklist of Individual Strength 
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Table 4. 9 Longitudinal study sample demographics. 
 
Whole Sample Care-as-usual Group Intervention (CBT) Group   
    Sample (N) 27 
 
  33 
  
  
    Gender (% males) 67% 
 
  58% 
  
  
    MIRS  1 = 0 
 
  1 = 2 (6%) 
  
  
        
2 = 9 
(33%) 
 
  2 = 8 (24%) 
  
  
        
3 = 9 
(33%) 
 
  
3 = 13 
(39%) 
  
  
        
4 = 9 
(33%) 
 
  
4 = 10 
(30%) 
  
  
    Phenotype (% mild) 22%     21%       
Variable 
mean 
(SD) 95% CI min-max mean (SD) 95% CI 
min-
max mean (SD) 95% CI 
min-
max 
sig. 
between 
groups 
Age 47.3 (10.3) 44.6-50 19-69 48.6 (10) 44.7-52.6 31-69 46.2 (10.5) 42.2-49.9 19-63 ns 
DM1-ActiC centile 
score 63.7 (18) 59-68.3 31-100 62.3 (17.5) 55.4-69.3 39-100 64.7 (18.5) 58.2-71.3 
31-
100 ns 
MDHI score 33.3 (18.3) 28.6-30 2-68.1 35.2 (16.4) 28.7-41.7 6.3-64.6 31.7 (19.8) 24.7-38.7 2-68.1 ns 
CIS – perceived 
fatigue 44 (6.3) 42.3-45.6 35-56 44.5 (6.5) 41.9 -47 35-56 43.6 (6.1) 41.4-45.7 
15.4-
20.4 ns 
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CIS – 
concentration 
problems 18.6 (7.3) 16.7-20.5 5-35 19.4 (7.6) 16.4-22.4 5-35 17.9 (7.1) 15.4-20.4 5-29 ns 
CIS – reduced 
motivation 17.9 (4.6) 16.7-19.1 7-26 18 (4.5) 16.3-19.8 9-25 17.8 (4.8) 16.1-19.5 7-26 ns 
CIS – reduced 
physical activity 16.9 (4.6) 15.7-18.1 3-21 16.6 (5.4) 14.4-18.7 3-21 17.2 (3.9) 15.8-18.5 7-21 ns 
HPA activity levels 
(average over 7 
days) 21 (11.5) 18-24 6.1-75 21 (14.4) 15.3-26.6 6.5-75 21 (8.8) 17.8-24.1 
6.1-
37.2 ns 
M5 ENMO 
(average of the 
most active 5 
hours of each day) 53.5 (34.8) 44.5-62.5 
11.8-
225.4 52.2 (43.4) 35-69.4 
12.2-
225 54.5 (26.5) 45-64 
12-
101.6 ns 
L5 ENMO (average 
of the least active 5 
hours of each day) 4 (1.1) 3.7-4.3 1.9-9.6 4.4 (1.4) 3.9-5 2.8-9.6 3.6 (.63) 3.4-3.8 1.9-5 0.016 
 
MIRS: muscular impairment rating scale, CIS: checklist individual scale, HPA: habitual physical activity, ENMO: Euclidean norm minus one 
(mg), M5 ENMO: most active 5 hours of the day, L5 ENMO: least active 5 hours of the day, SD: standard deviation, 95% CI 95% confidence 
interval, ns: non-statically significant. 
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Table 4. 10 Groups' progression over time. 
Care-as-usual Group (N = 27) 
Mean change 
over 5 months 
(N = 25) 
SE 
mea
n 
Sig. 
(2-
tailed) 
Mean change 
over 10 months 
(N = 26) 
SE 
mean 
Sig 
(2-
tailed) 
Mean change 
over 16 months 
(N = 23)  
SE 
mea
n 
Sig. 
(2-
tailed) 
DM1-ActiC centile score +0.3 2.0 ns -0.2 1.9 ns -0.3 2.2 ns 
MDHI score -5.4 3.2 ns -2.4 2.5 ns -3.3 2.8 ns 
CIS – perceived fatigue -1.9 * 1.3 ns -3.0 * 1.2 0.02 -3.4 * 1.6 0.04 
CIS – concentration problems +0.2 1.4 ns +0.4 1.5 ns +0.6 1.7 ns 
CIS – reduced motivation -0.2 * 0.9 ns -0.6 * 1.1 ns -1.4 1.2 ns 
CIS – reduced physical activity -0.1 * 0.8 ns -0.5 * 0.9 ns -0.2 * 0.9 ns 
HPA activity levels (average over 
7 days) -1.2 1.1 ns -1.4 * 1.3 ns -2.5 1.4 ns 
M5 ENMO (average of the most 
active 5 hours of each day) -0.0 3.3 ns -1.4 * 3.8 ns -6.3 4.5 ns 
L5 ENMO (average of the least 
active 5 hours of each day) -0.6 0.3 ns -0.6 0.3 ns -0.7 0.4 ns 
 
 
          
 88 
 
 
 
Intervention group (Cognitive 
Behavioural Therapy- CBT)   
(N = 33) 
Mean change 
over 5 months 
(N=32) 
SE 
mean 
Sig. 
(2-
tailed) 
Mean change 
over 10 months 
(N = 30) 
SE 
mean 
Sig 
(2-
tailed) 
Mean change 
over 16 months 
(N = 28)  
SE 
mean 
Sig. 
(2-
tailed) 
DM1-ActiC centile score +4.8 2.1 0.03 +2.7 1.9 ns +3.0 2.4 ns 
MDHI score -7.7 2.5 0.00 -7.2 2.1 0.002 -8.5 2.7 0.004 
CIS – perceived fatigue -11.6 * 1.7 0.00 -10.5 * 1.8 0.00 -10.6 * 1.8 0.000 
CIS – concentration problems -1.6 1.0 ns -1.1 1.0 ns -1.1 1.4 ns 
CIS – reduced motivation -5.0 * 0.9 0.00 -3.5 * 0.8 0.00 -3.1 1.3 0.028 
CIS – reduced physical activity -5.6 * 0.9 0.00 -4.7 * 0.7 0.00 -4.6 * 0.8 0.000 
HPA activity levels (average over 
7 days) +0.2 1.3 ns +1.3 * 1.2 ns +0.2 1.9 ns 
M5 ENMO (average of the most 
active 5 hours of each day) +2.2 3.9 ns +5.4 * 4.1 ns +1.1 5.9 ns 
L5 ENMO (average of the least 
active 5 hours of each day) +0.1 0.2 ns +0.1 0.1 ns -0.1 0.2 ns 
 
MIRS: muscular impairment rating scale, CIS: checklist individual scale, HPA: habitual physical activity, ENMO: Euclidean norm minus one 
(mg), M5 ENMO: most active 5 hours of the day, L5 ENMO: least active 5 hours of the day, SD: standard deviation, 95% CI 95% confidence 
interval, ns: non-statically significant. * Significant difference between groups at this point (Mann-Whitney U Test).  
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Table 4. 11 Sample comparing classic and mild (late onset) phenotype 
subgroups at baseline and progression over time. 
 
 5 
4.4. DISCUSSION 
 
The systematic review revealed a clear increasing trend to utilize activity monitors 
in all forms of neuromuscular diseases ranging from more basic pedometers to 
Time Point 
GENEActiv 
report 
Classic 
Mean (SD) 
Mild 
Mean (SD) 
sig. between 
groups 
Baseline 
HPA 24 hours 18.5 (9.4) 31 (4.3) 0.008 
M5 ENMO 45.8 (26.8) 81.2 (11.4) 0.002 
L5 ENMO 4 (1.3) 3.8 (.3) ns 
5 months 
HPA 24 hours 18.8 (10.6) 26.2 (4.3) 0.026 
M5 ENMO 48.6 (32.7) 71.9 (15.2) 0.015 
L5 ENMO 3.8 (.9) 3.6 (.5) ns 
sig. from 
baseline 
ns ns   
10 month 
HPA 24 hours 18.9 (8.1) 26 (7.8) 0.031 
M5 ENMO 50.2 (25.4) 68.3 (26.4) ns 
L5 ENMO 3.7 (.7) 3.9 (.4) ns 
sig. from 
baseline 
ns Ns   
16 months 
HPA 24 hours 16.6 (7.1) 33.2 (17.8) 0.002 
M5 ENMO 41.8 (20.5) 87.9 (48.7) 0.004 
L5 ENMO 3.6 (.5) 3.6 (.5) ns 
sig. from 
baseline 
ns Ns   
HPA: habitual physical activity (24 hours average ENMO-mg over 7 consecutive 
days), M5 ENMO: most active five hours of the day (average ENMO over 7 
consecutive days), L5 ENMO: least active five hours of the day (average ENMO 
over 7 consecutive days).  
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more sophisticated tri-axial accelerometers. However, when compared to other 
diseases with motor impairment, activity monitoring in neuromuscular disorders is 
still at an early stage of implementation and understanding. There is a clear need 
to encourage the introduction of these novel tools into research and clinical 
practice and to increase the awareness among health practitioners and 5 
researchers of their clinical usefulness (52). This could be improved by a 
conscious use of the existing tools by researchers and an appropriate selection of 
monitoring methodologies when implementing them to neuromuscular disorders. 
Byrom et al. (160) and Dilon et al. (189) proposed certain criteria to increase the 
level of confidence when assessing HPA with activity monitors by suggesting the 10 
use of triaxial accelerometry (like ActiGraph, RT3 and Actical) for at least 6 
consecutive days of suggested ‘wear time’ and for at least 10 hours per day 
which was only followed in three of the identified studies (177, 183, 184). 
Common placement sites have been waist and hip (160). However distal joints 
have shown better compliance by the participants (160, 190). There was a clear 15 
lack of validity and reliability testing among the identified studies, which 
emphasizes the need to understand this technology better and to invest more in 
the investigation of its use and applicability in neuromuscular diseases. We 
suggest including the use of activity monitors in DM1 in future discussions related 
to the selection and standardisation of outcome measures in DM1 such as the 20 
OMMYD and the TREAT-NMD meetings (27, 144). Conclusions from this 
systematic review about an activity monitor of preference are not possible from 
this review as these were not compared with each other and only a few details 
regarding logistical issues were reported. This would require extensive reliability 
and validity work in the target population, which was not the aim to the literature 25 
review. Still, similar reviews have concluded that tri-axial accelerometry is 
feasible, and where raw data are accessible this should be investigated and 
adapted further for each cohort of interest (160, 191-193). In conclusion, there is 
a need to investigate this type of devices further and the pressure to identify 
feasible tools with valid outputs to measure physical activity parameters in DM1.  30 
 
This study explored the validity of the tri-axial accelerometer (GENEActiv) in DM1 
participants. GENEActiv showed potential when assessing different walking 
paces in this disease, showing sensitivity to differentiate the affected from non-
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affected and a difference in range values between walking speeds, while there 
was no difference in the standing-still position. In the walking tests, the results 
from the wrist demonstrated closer or overlapping 95% CI between the DM1 
participants and the healthy participants which was not the case for the ankle 
data. This might suggest the ankle as a better option to distinguish walking 5 
periods of a DM1 participant with a comfortable speed, detecting outputs between 
33 and 41 ENMO/minute. The findings of this study were not comparable to 
previously published GeneActiv wrist activity thresholds as these include oxygen 
consumption on their final scores (154). Table 4.2 proves the concept that each 
device records higher acceleration values with each activity intensity increment 10 
and these values differ in slower walkers and runners (e.g. DM1) from faster 
ones. There is a significant impact on accelerometer location when translating 
raw data into meaningful outputs. Ankle reports differ significantly from wrist ones 
when walking and this difference disappears when increasing speed into running; 
however, this effect is less evident in the DM1 cohort that can be explained by an 15 
impaired running capability as shown before. Unfortunately, there is a lack of 
GeneActiv ankle-based accelerometer studies that could enrich these findings but 
it has already been suggested that ankle-worn devices may have the highest 
correlation to actual physical activity energy expenditure (194, 195).  Still, a 
crucial need in this field is the identification of intensity thresholds that can 20 
differentiate the movements recorded as mild, moderate or vigorous activity-
intensities.  
 
ICC was estimated with a two-way random model which assumes that each 
participant was measured by each accelerometer at the same time, and that the 25 
used accelerometers properly represent a larger population of similar devices (60, 
62). There was an excellent level of agreement within each accelerometer’s 
measurements for all waking (per minute) scores (61). Kayes et al. (156) 
performed a similar study, exploring the Actical accelerometer in people with 
multiple sclerosis, also finding low ICC scores for sedentary activities and higher 30 
scores for more vigorous and rhythmic activities such as the 6MWT; we have to 
consider that these results come from a different monitor that uses different 
interpretation outputs and based algorithm. ICC decreased for the 6MWT-per-
second estimations, which might be explained by the variation in body position 
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from second to second. This effect disappears when summarised to counts per 
minute.  
 
A Bland-Altman plot presents the average bias (or average of the differences) 
between one accelerometer report and another, and the closer to zero the result 5 
is the more intra-accelerometer reliability there is. These plots reveal good intra-
accelerometer reliability when comparing accelerometers of the same limbs 
between each other but not when comparing upper limb (wrist) to lower limb 
(ankle). This reliability reduces with the increment of speed (i.e. running test). 
This is a common case scenario with accelerometers as these devices can 10 
exhibit a phenomenon where a speed increment could either emphasize walking 
disturbances that reflect differences between the limbs or due to a frequency-
dependent filtering effect of accelerometers (196-198). When wrist values are 
plotted against ankle values, these (i.e. wrist) revealed a strong linear trend with a 
widening difference at the lowest and highest extremes of acceleration (Figure 15 
4.4). These findings complement the finding of higher mean values recorded by 
the ankle compared to the wrist when walking and strongly suggest that 
algorithms created for activity outputs validated for the wrist cannot be translated 
directly to the ankle when referring to ambulation or standing-still positions. The 
ankle has already been suggested before as the most appropriate site for 20 
placement when aiming to classify different speeds in activity, in particular to 
distinguish low-speed walkers (190, 199). 
 
The use of accelerometers to assess HPA was shown to be feasible but with an 
issue of lost data or devices not returned and an average of only 80% of returned 25 
devices suitable for data extraction. In the OPTIMISTIC study the percentage of 
devices returned and suitable for data extraction (i.e. non-faulty) was 84% from 
the total of patients attending the randomization visit, 80% from visit three and 
86% from visit four. After the cleaning process and excluding accelerometers with 
incomplete information or extracted data not fulfilling the pre-defined inclusion 30 
criteria only 79%, 75% and 78% (respectively) from the total sample were suitable 
for analysis. From all patients still enrolled at visit 4 (i.e. 10 months after 
randomization and visit established as the time point to measure the effect on the 
primary outcome), only 58% had complete data for analysis from each of the 
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visits. These numbers compare with other epidemiological reports, emphasizing 
the need to estimate data lost from these devices when declaring sample size 
and the importance of searching data quality from those not lost, which was done 
in this study (200, 201). The assessors’ experience with the device software 
certainly facilitated the process but it was recognised that there was a need for a 5 
period to become familiar with the data-handling process.  
 
Finally, this study presents for the first time objectively and in detail HPA levels of 
a fatigued DM1 population. This study allowed for comparison with other relevant 
cohorts such as the CFS group, a disease characterised by altered daily life 10 
activity patterns (202, 203). This CFS population had an average of 62 
counts/day when awake (measured by ActivLog), which is close enough to the 
previously reported average of 60 counts/day that helped define the cut-off value 
for ActivLog to determine active days from passive days in this population and 
establish treatment accordingly (203). This validates the CFS sample (even when 15 
small) as a good representation of the disease regarding activity patterns. Though 
reporting less severe levels of fatigue than the CFS group, the DM1 group 
showed the lowest active HPA levels. Not all CIS scores showed a strong 
correlation with the activity patterns, but this questionnaire is thought to assess 
factors that impact on fatigue and not the other way around. However, the strong 20 
correlation between the reported reduced activity and the low objective HPA 
levels justify the conclusion that participants report their activity levels quite close 
to reality. This is not always the case in pervasively passive populations (204, 
205).  
 25 
There was no statistically significant change in HPA levels over time for either of 
the subgroups analysed but there is a clear suggestion of a trend of progression 
that differs between the group under an intervention and the standard care one. 
This trend is more drastic in the M5 ENMO values. Additionally, after 10 months 
of study follow-up, at the visit that corresponds to the primary endpoint of the 30 
overall OPTIMISTIC study and the time when the intervention would be finished, 
there was a significant difference between allocation groups and the constant 
significant difference between mild and classic was not detectable for the M5 
ENMO values. This could be explained by a pick effect of the intervention but to 
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confirm this conclusion, ANCOVA estimation, controlling for treatment allocation, 
should be performed. However, testing the effect of the intervention was not in 
the scope of this thesis.  
 
Mild participants’ HPA levels differ significantly from the classic onset phenotype, 5 
not reaching the levels of our healthy volunteers’ cohort but scoring somewhere 
between the CFS group and the healthy volunteers. As suggested before, when 
considering the ‘ideal DM1 patient’ for a clinical trial the significant differences 
between phenotypes should be considered for stratification or inclusion criteria, 
as these can considerably impact the outcome measure results (15, 158). 10 
 
SEM% estimation was performed using reports of the care-as-usual (control) 
group at each time point. The results showed that if an intervention aims to reflect 
its efficacy on HPA levels measured with a GENEActiv accelerometer placed 
around the ankle, the smallest difference expected to claim a real change for a 15 
group of subjects should be 13% for the average HPA levels and 17% for the M5 
ENMO (206, 207). 
 
As performed in the previous chapter (study 1), based on these results, an 
attempt of power and sample size estimations was performed. For a two-arm 20 
study, a sample size of at least 85 participants per group, or 52 participants 
cohort for a one-arm study, would be required to allow the detection of a 20% 
difference or change, in the average HPA levels with 90% power (21, 62). This 
also assumes that patient populations are similar to this study, and that there is 
no significant variation on the HPA mean and standard deviation values. In this 25 
case the 20% difference or change represents 1.5 times the estimated SEM% 
giving chance for a real clinical change over the expected systematic error. Still, 
the level of change reflecting a significant change in patients’ life needs further 
investigation. 
 30 
4.5. CONCLUSIONS 
 
When interpreting reports of activity monitor data caution is needed as the 
majority of these outputs come from validation studies performed with healthy 
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volunteers. Identified outcome measures such as energy expenditure or physical 
activity levels in neuromuscular disorders (208-212) are not as straightforward as 
expected. In the case of DM1, gait abnormalities such as impaired balance and 
mobility, and reduced endurance, certainly impact on the outputs obtained from 
accelerometers and other activity monitors (213). Testing the validity and 5 
reliability of an activity monitor in DM1 patients before implementing the device in 
a clinical trial will help researchers understand the possible strengths and barriers 
when using these tools in this particular group. 
 
Significant differences are apparent when comparing two different monitor 10 
placement-sites but when attached to the same body location (different sides) 
comparisons seem valid. This study demonstrated that GENEActiv worn around 
the ankle can provide reliable data about DM1 ambulatory patterns in clinical 
settings and activity levels from daily life monitoring. Using objective methods, 
DM1 fatigued patients recorded significantly lower activity level in their daily life 15 
not only when compared to a healthy cohort but also against a chronic fatigued 
population. This study provides a significant amount of data to generate reference 
values for other researchers interested in utilizing this tool or ENMO as a unit 
measure when assessing HPA in DM1 patients.  
 20 
Identifying the appropriate HPA measurement tool, either objective, subjective or 
both, and understanding its deliverables in the best possible way will not only 
generate high-quality data but will allow an efficient investment of time and 
resources when investigating HPA in any neuromuscular disorder. Future studies 
are needed to understand the underlying source of HPA differences and identify if 25 
there are specific activity-types that could be approached for health improvement.  
The methodology used in this study to assess HPA in DM1 (ankle-worn tri-axial 
accelerometer summarised in ENMO per 24 hours obtained from seven 
consecutive days of ≥23-hours of wearing time excluding at least the first and last 
days of the real expected monitoring period) can be applied in future DM1 clinical 30 
trials and this study will provide them evidence justifying their tool and 
methodology selection plus reference data to compare to.  
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CHAPTER 5. DISCUSSION 
 
Currently, there is no cure for DM1, but the potential of new treatment strategies is 
more visible today than just a couple of years ago (214, 215). Identifying 
appropriate outcome measures that are feasible, valid and reliable within the DM1 5 
population is essential to monitor disease progression and the effect of any 
intervention. A potential target for future interventions in DM1 should be to 
improve these patients’ performance and participation in daily living activities (18). 
Outcome measures (OM) can evaluate different aspects of the disease, from 
body function and structures to participation and involvement in daily life (216, 10 
217). DM1 is a multi-systemic disorder affecting many functions and organs. DM1 
is also highly variable from severely disabled infants to near-normal, minimally 
affected adults. This variability requires careful characterization and stratification 
of patients for research, including research into OM. Moreover, a single OM might 
be influenced by more than one of the phenotypic features present in a patient 15 
with DM1, e.g. performance in the 6-Minute Walking Test (6MWT) may be 
influenced not only by muscle strength and endurance, but also by lung 
capacity(218, 219), cardiac disease(220), metabolic or endocrine 
abnormalities(221), and impaired cognitive ability(222, 223), all of which can be 
found in DM1. Therefore, it would not be appropriate to conclude that a change in 20 
the 6MWT over time is due to a change in muscle strength exclusively, as long as 
the other parameters are not controlled for. Assessing disease with complex 
outcomes can be an advantage but to fully understand changes to function and 
well-being of a DM1 patient, usually a battery of complimentary tests, both 
technical (laboratory results, imaging) and functional outcomes are required. This 25 
thesis focuses on exploring the use of three functional outcome measures (FOM) 
established by the outcome measures in myotonic dystrophy type 1 (OMMYD) 
consortium in 2015 and an accelerometry-based activity monitor. A clearly 
defined methodology to use these outcome measures and knowing the expected 
margin of error is of extreme importance when deciding on tools and designing 30 
protocols for future clinical trials in DM1. The properties analysed to evaluate the 
integrity of the selected outcomes include feasibility, reliability, validity, variability 
and responsiveness. These properties will establish the degree of error and what 
outcome is produced when utilized in this specific population (224).  
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Due to the sample size and the distribution of phenotypes and severity in this 
study, we are confident to present reliable estimates for those adults from the 
DM1 population who are most likely approached for clinical trials. More than 60% 
of the participants from the OPTIMISTIC (NCT02118779) and PHENO-DM1 5 
(NCT02831504) trials were recruited through the UK Myotonic Dystrophy Patient 
Registry. This self-initiated registry includes an element of motivation and ability 
and represents the first line of recruitment for clinical trials (75). 
 
Both studies start with a cross-sectional study to obtain a “snapshot” of our 10 
sample and to verify or reject any hypothesis of group or subgroup differences. 
Correlation results reported at this point were to analyse associations of variables 
but not to conclude on any causality as a longitudinal analysis would be required 
to confirm this. The introduction of a test-retest design in study 1 was chosen 
because of a justified need to explore any learning and/or fatigue effects that 15 
might impact on the results. Finally, the longitudinal analysis was performed to 
identify any possible change in time that could be attributed to a real change in 
the participants’ characteristics and not to a systemic error and to support the 
responsiveness capacity of the outcome in question. 
 20 
5.1. STUDY 1 
 
The first set of outcome measures explored are three examples of outcome 
measures of functional capacity, describing each individual’s ability to execute an 
action in a specific standardised and controlled circumstance (216). Since the 25 
OMMYD consortium proposed a test battery of functional outcome measures 
(FOM) considered clinically relevant and robust enough for execution in clinical 
trials in adults with DM1, efforts have been invested into validating and exploring 
the feasibility of their use (28). The 6 minute walk test (6MWT) has been explored 
in adults with DM1 before showing high relative and absolute reliability (39). One 30 
other study reported preliminary exploratory results from the 10-mWT and from 
the 10-meter max speed walk test (not run) as possible outcomes measuring 
balance and risk of falling (43). However, to our knowledge, this is the first time 
that full validity, reliability and responsiveness in DM1 have been tested for the 
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following tests (142): [1] timed 10-meter walk test (10-mWT) – comfortable speed; 
[2] timed 10-meter walk/run test (10-mW/RT); and [3] 30-second sit and stand test 
(30SSS).  
 
Despite proving once more an excellent test-re-test relative reliability (i.e. 5 
coefficients ranged from 0.98 to 0.99), the systematic variability identified 
between test trials (first and second) justifies the need of repeated trials when 
implementing these tests. The correlation levels shown with SARA, muscle 
strength and disease-specific patient reported outcomes, plus the sensitivity to 
distinguish participants with a reported ability to run from those that do not and to 10 
distinguish participants with proximal muscle weakness, validate these outcomes 
as suitable surrogate markers of disease severity. Finally, the mean change 
detected after one year of follow-up that was higher than the minimum expected 
standard error of measurement (SEM) validates their sensitivity to detect real 
change and suggests a significant natural disease progression measurable within 15 
12 months.  
 
This study suggests the following cut-off points to identify more significantly 
impaired patients: [1] 9 sec for the 10-mWT; [2] 6-7 sec for the 10-mW/RT; and 
[3] 11 stands for the 30SSS. These cut-off values could also be considered for 20 
clinical practice as potential identifiers of participants requiring special attention or 
interventions such as assistive-walking devices, orthotics and exercises. To 
reduce inter-test variability and increase the chances of addressing a real change 
over time we recommend considering for analysis the average of all completed 
trials for the 10-mWT, 10-mW/RT and 30SSS. However, in the longitudinal 25 
analysis, the biggest percentage of change over time was shown in the change of 
the total stands of the 30SSS and in the best-trial score for each of the FOM. So, 
considering both, average and best score could be an option. On the other hand, 
to suggest ‘total stands’ of 30SSS as the score to count, we would first 
recommend a standardised assessment methodology that would specify the input 30 
of encouragement to complete the three test-trials and a standard time of rest in 
between. 
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5.1.1. 6MWT alternative outcomes 
 
6MWT is the most commonly used outcome measure in neuromuscular diseases 
to date (225, 226). However, the originally-specified corridor length required for 
the 6MWT has been a barrier to implementation into clinical trials particularly 5 
when involving unexperienced sites (87, 227, 228). Additionally, there is a need 
for more than one single trial to reduce test-to-test variability (39, 129, 131, 133, 
134, 229). Identifying outcome alternatives with more flexibility for different 
settings and suitable for trials involving long visits and additional assessments 
could improve the research experience for participants and researchers. With this 10 
study we suggest that the combination of the 10-mWT and the 30SSS can 
substitute for the 6MWT. By performing two trials of the 10-mWT and an attempt 
for three trials of the 30SSS important factors interfering in daily life participation 
in DM1, such as the ability to walk, balance and fatigue, can be addressed (3, 18, 
43). Additionally, with this combination of tests we can assess balance (and 15 
possible risk of falling), which, in the case of DM1, will provide a wider picture of 
the disease burden in relation to functionality. Tyson et al. (84) performed a 
systematic review, aiming to identify and score psychometrically robust and 
clinically feasible walking-based outcome measures in neurological disorders and 
selected the 10-meter walk test as among the best three outcomes. In this case 20 
we do not have any data suggesting that the 10-mWT is better option than the 
6MWT as both are feasible, valid and with same levels of reliability; both tests 
required more than one trial to increase reliability and both correlate in similar 
degree to muscle strength and patient reported outcomes (PRO). The 
advantages over the 6-minute walking test are: [1] a lower risk for a flooring 25 
effect, allowing for the inclusion of the most impaired patients able to walk short 
distances; and [2] a corridor length with more flexibility to be implemented in 
clinical settings and in research sites with variable building distributions.  
 
5.1.2. Assessing fatigue and endurance 30 
 
Fatigue and endurance can also be measured with the 6MWT (230). Shorter (in 
time) tests have been found appropriate to assess walking capability, but risk to 
miss the fatigue effect detectable by a reduction in speed in the last minutes of 
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the 6MWT (231). However, based on this study experience and previous reports 
in other diseases, the 30SSS, especially when tested with repeated trials, can be 
used for assessing fatigue and cardiovascular fitness but this will need to be 
explored further (232-236). In this study the examiners reported that the primary 
reason for stopping the 30SSS and not completing the 3 trials was participants’ 5 
fatigue. Even though it was not established whether there was a standard rest of 
period between trials or between tests, all examiners were instructed to give 
sufficient resting time in sitting to the participant between tests and to guarantee a 
heart rate stabilization before starting the 30SSS (i.e. after the 6MWT). Between 
each 30SSS trial patients were asked for their approval to continue and when a 10 
participant reported feeling too tired to continue the test would stop. Finally, 
examiners have discussed the possibility of a visible impact of the 30SSS on 
participants’ heart rate and a visible higher exertion than that perceived after the 
6MWT. Upon additional analysis performed during this study, the number of 
stands completed at second 20 of the 30 seconds sit and stand test were 15 
recorded and the performance estimated for the last ten seconds had a mode of 
80% and an average of 89% (median 87%; SD28%). This estimation and the 
direct correlation with perceived fatigue should be considered for future studies. 
One-minute-length sit and stand test has been used in chronic obstructive 
pulmonary disease to assess functionality and exercise performance (232, 236, 20 
237); by eliciting more than one 30-seconds-length trial, it is possible to reach the 
fitness challenge threshold that would make this test a tool to evaluate exercise 
tolerance as such as functional capacity. In this case-scenario, considering the 
‘total stands’ score as the outcome of analysis will make good sense. Similarly to 
6MWT, the 30SSS can also be influenced by the motivation of the patient(238) so 25 
a standardisation of the encouragement lines given before and along the test 
most probably will increase accuracy. These findings suggest the need to explore 
further this test as a possible assessment measuring fatigue and fitness levels in 
patients with DM1. This test (i.e. 30SSS) requires less time and space than the 
6MWT and can be performed in a variety of location conditions. 30 
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5.1.3. Assessing balance and risk of falls  
 
Impaired balance and a high risk of falls affect the DM1 population and relate to 
disease severity and muscle weakness (42, 43, 45, 126). Identifying participants 
with a higher risk of falling may help clinicians to intervene and to identify risk 5 
factors that can be controlled or prevented. The ability to stand up from a chair is 
an important component of maintaining independence and is a movement that 
depends on stability and balance (238). Sit and stand tests like the 30SSS have 
been suggested as good predictors of fallers in populations with high risk of falls 
like DM1 (43, 44, 238, 239). 10 
 
5.2. STUDY 2 
 
The second study corresponds to an accelerometry-based device as a potential 
measurement tool of a proband’s performance (148, 240). Performance describes 15 
what a person actually does in his/her daily life (19, 217). The aim of this study 
was to gain more insight into the validity of one of these devices, GENEActiv, 
when assessing functional tasks and when measuring habitual physical activity 
(HPA) in daily life.  
 20 
5.2.1. Systematic Review 
 
After identifying the current interest in the neuromuscular field to implement 
activity monitors into research and being aware of their potential as outcome 
measures that could address patients’ participation in daily life, a systematic 25 
review was performed, aiming to collect and analyse all studies reporting HPA in 
neuromuscular disorders (143, 144, 241). Challenges in measuring HPA in 
individuals with physical impairment are how to measure activity in a reliable and 
valid fashion, ensuring that the data provided are representative of the targeted 
population’s real performance. Accelerometry-based devices are in current use in 30 
clinical trials in DM1. The OPTIMISTIC trial included an ankle-worn GENEActiv as 
part of its outcome measures (69). However, to our knowledge, there is no 
previous publication reporting the validity and reliability of this monitor in DM1 
(148).  Never the less when placed around the ankle. 
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5.2.2. Validity of an accelerometry-based device in DM1 
 
Comparing acceleration scores with direct observation is an approach useful to 
establish criterion-validity of an activity monitor. GENEActiv placed at four 5 
different sites proved capable of capturing acceleration at different intensities of 
ambulation. Overall, all accelerometer site placements were significantly 
associated with the motion speeds performed at each task but wrist and ankle 
outputs cannot be translated to each other straightforwardly. Ankle-placed 
accelerometers performed better as sensitivity tools to differentiate ambulation 10 
speed between DM1 and healthy controls. The role of muscle weakness and 
impaired walking reflect on the reduced speedup of the upper limbs when 
compared to the ankles at the 10-meter walk/run test, more significantly when 
analysing the classic phenotype independently. These data cannot be translated 
into energy expenditure; for this, a comparison will be required against doubly 15 
labelled water (2H2 18O) method, in which after a dose of the liquid compound, the 
eliminated 2H is subtracted from the amount of eliminated 18O independently and 
equals the amount of CO2 produced, representing the amount of energy 
expenditure from the moment of ingesting the liquid until the moment of 
elimination (209).  Finally, due to the physiological variations in this population it 20 
will be invalid to employ predictive equations generated for other populations who 
are not at the same risk level. 
 
5.2.3. Habitual Physical Activity in DM1 
 25 
Byron et al. and Strath et al. (51, 160) proposed best practice guidelines when 
implementing activity monitors into research involving populations with physical 
impairments. They agree on the idea to avoid summary endpoints if these have 
not been validated before and to refer to raw data instead. The shorter the time 
sampling interval (epoch length or pre-defined activity bouts) the higher the 30 
chance to collect informative data from passive or slower participants. It is 
important to establish and employ standard methods for obtaining, cleaning and 
analysing data that, regardless of reducing the sample number, guarantee 
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reliable data. As we are dealing with an unknown sample regarding compliance 
and day distribution of activity patterns, in OPTIMISTIC we requested participants 
to wear the device full-time for two weeks. We excluded those not worn for at 
least 23 hours for a minimum of 7 consecutive days guaranteeing the inclusion of 
a weekday. This protocol showed feasibility with about 20% of data lost at every 5 
visit and a full study completion of only 58%. Lessons learned from this study may 
be used to develop a better-established logistics-system that could facilitate staff 
and study participants’ management and understanding of the devices. In our 
systematic review we propose a guidance-checklist to follow whenever 
considering including an HPA measurement tool (including accelerometers) into a 10 
clinical trial or when reporting its use in neuromuscular disorders.  
 
By combining previous experiences with activity monitors and the experience 
from the OPTIMISTIC trial, loss of data and participants’ compliance are 
important issues to keep in mind prior estimating sample size, particularly if HPA 15 
as assessed by activity monitor is the primary outcome (51). There are, however, 
practices that presume better compliance such as: choosing distal joint areas 
(thigh, wrist or ankle) over centre-body areas like hips or chest (190, 242), a 
minimum of 7 days of requested monitoring to achieve at least 5 days of valid 
data and a minimum of 10 hours per day of wearable time.  20 
 
5.3. BIAS MINIMIZATION 
 
DM1 is a complex condition that presents a wide spectrum of severity, symptoms 
and impacts on functioning. An appropriate stratification of the population will help 25 
to enhance the clinical understanding of the natural disease progression (15, 118, 
158, 243). The differences observed between the classic and the mild 
phenotypes were significant along all outcomes presented and their progression 
as sub-groups will be studied further. The differences between the sexes shown 
in all outcome measures should be noticed when comparing samples with 30 
different sex distributions (45, 118). Indeed, this suggestion has been made 
before, encouraging researchers to consider phenotype and sex separately when 
planning health standards of attention or when designing any future studies (15, 
118, 158, 243). When designing a clinical trial protocol, especially randomized 
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controlled trials (RCTs), a plan for the minimization of potential bias should 
consider sex and the disease phenotype (118, 244).  
 
5.4. STUDY LIMITATIONS  
 5 
For a study searching for ideal outcome measures in a rare disease, few general 
limitations have to be mentioned (245). The healthy controls group differed in age 
and sex distribution from the DM1. However, even after including age and sex as 
possible confounders in the model, the differences between groups remained 
significant. This can be added to the fact that the milder phenotype prevailed 10 
among the older DM1 population with greater chances of showing a better 
performance, contrary to what is expected from a healthy population. Still, an 
ideal comparison between groups would come from age-matched groups.  
 
Intra-rater reliability has been robustly assessed before (44, 142) and once more 15 
with this study, but inter-rater reliability has not been studied in DM1. However, 
publications in other neurologically impaired diseases have shown high inter-rater 
reliability scores for the walking tests in other neurological disorders (84, 125, 
246). To properly assess these FOM feasibility and to influence properly on trials 
preference, an appropriate patients’ feedback questionnaire or experience 20 
recollection would have been ideal to enrich information about feasibility. 
Enhancing the participant’s clinical trials experience could improve study 
compliance and is one of the central pillars of quality in healthcare attention (247). 
 
All these FOM were performed on the same day within a long study visit that 25 
involved other physical assessments and a large number of questionnaires to 
complete. On average these visits lasted between 4 and 6 hours, which most 
probably impacted on the participants’ performance during the assessments. 
From the start of the study there was an agreement to retain the order of 
assessments for all participants: prioritizing cardio-respiratory assessments at the 30 
beginning of the visit, followed by patient-reported outcomes and finalized with 
FOM and strength assessments. Additionally, as an attempt to minimize 
variability due to fatigue and motivation, the time of assessments and the 
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sequence followed would be recorded for each participant and we would attempt 
to replicate the sequence on the follow-up visit.  
 
Unfortunately, at the time of this thesis, not all of the PHENO-DM1 study follow-
up visits had been carried out limiting the longitudinal study sample size. Having 5 
the full data of longitudinal analysis may provide additional information to 
effectively stratify data according to participants’ sex and disease phenotype. The 
analysis of a second visit will allow the identification of cases with no significant 
measurable changes over time and most probably attained their own highest 
possible scores (i.e. ceiling effect) (248).  10 
 
We have to be cautious when generalising the disease change over time as this 
longitudinal studies have 10 to 12 months between assessments, which may be 
too short or too long for a treatment to show any effect (245). Still, treatments are 
needed for long-term effects in addition to the short-term effects and knowing the 15 
progression trend of a disease-sample over a year will support the decision-
making process of a change expected to reflect an intervention effect.  
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6. CONCLUSIONS AND CLINICAL IMPLICATIONS 
 
The results presented in both of my sub-studies can be used to propose outcome 
measures that provide an objective picture capacity and performance of the DM1 
patient. This study established the reliability and validity of a set of functional 5 
outcome measures and of an accelerometry-based activity monitor appropriate 
for use in mild to moderately affected, ambulant adults with DM1. Using valid and 
reliable outcome measures in this disease will provide a better understanding of 
its complexity and ultimately will support the identification of effective treatment 
opportunities.  10 
 
6MWT continues to be an assessment with high correlation scores to other 
disease severity outcomes such as: muscle strength; the SARA and patient-
reported outcomes. However, the three-studied FOM either independently or in 
combination seem to be good alternatives, as they show strong correlation values 15 
with disease severity outputs and, as shown in my study, have proven validity and 
reliability in patients with DM1. 
 
Protocol recommendations derived from my study are: [1] consider including 
more than one assessment of functional capacity (i.e. FOM) and one 20 
measurement of performance (i.e. activity monitor) regardless of correlating 
between each other, these do not substitute each other and both types of 
outcomes are significant when explaining the level of disease impairment; [2] 
follow a standardized protocol that has been previously used in DM1 will allow 
intra-studies comparability; [3] perform FOM at least twice whenever possible and 25 
use either the average or the best score as the test results; [4] when using any 
activity monitor, consider a prior-protocol validation test if this has not been 
performed before; [5] identify the possible differences between the sexes and 
disease phenotypes (classic and mild), this is essential when studying disease 
progression of a sample with variability within the cohort; minimising a sample 30 
randomization for these factors (sex and phenotype) should be considered; and 
[6] there is minimal expected change of 5% (0.5 sec) for the 10-mWT, 8% (0.4 
sec) for the 10-mW/RT and 10% (1.4 times) for the 30SSS, and 13% (2.7 mg 
ENMO) for the HPA (accelerometry) reports, that can be attributed to 
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measurement error and should be considered when designing a trial and when 
estimating the power and sample size.  
 
The choice of outcome measure for future trials should be guided by the domain 
of the disease that an intervention is likely to impact on (245). When combined 5 
FOM and objectively measured HPA patterns in DM1, researchers can get a 
more complete picture of the real functionality of the patient including information 
about their capacity and their performance in daily life. An ideal intervention 
should impact on both aspects of functionality and translate into a better quality of 
life. 10 
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7. FUTURE DIRECTIONS 
 
This study represents a substantial advance towards the standardization of 
disease-specific outcome measures in DM1. Questions remain about the design 
of a clinical trial protocol and the proper definition of outcome measures that will 5 
portray the participant’s overall disease status and progression. 
 
One of the first plans for the short-term future is to perform as similar study focus 
on the upper extremity functionality and strength; assessing the validity and 
reliability of the Nine-hole Peg test (9HPT) in order to complete the deep 10 
exploration of all OMMYD FOM. 
 
Impaired balance with a risk of falling has been recognized as a frequent and 
common problem in adults with DM1 (42, 43, 45, 126). Still, the standards of care 
in the UK do not include a proper assessment and prevention of falls programme 15 
for DM1 patients (16) and is not yet recognized as a cohort at risk which may limit 
access to local fall services (249). There is a current need to perform a project 
aiming to increase the awareness of this issue within DM1 healthcare-personnel 
and researchers may be warranted. We recently developed a multinational survey 
to estimate the risk of falls and estimated an odds ratio of 1.6:1 of every DM1 20 
adult <65 over every healthy adult >65 years old which represents the population 
with a higher risk of falling and the cut-off age to become eligible to enter falls 
clinics. By identifying an appropriate tool to predict falls that can be performed at 
clinic standards could facilitate the identification of patients that need attention 
and falls rehabilitation/education in a timely fashion. SARA and 30SSS are 25 
potential falls predictors; however, to validate these fully, we proposed a 
longitudinal recollection of falls and a study of associations with any gold standard 
balance assessment tool (234). 
 
The use of accelerometers is lagging behind in the validation and harmonization 30 
efforts as the importance of these tools comes from the translation of raw data 
into clinical outputs with significant values. There is an initial need to identify 
physical activity levels and/or energy expenditure scores that can translate from 
the counts (ENMO/min) reported by GENEActiv. This will raise the interest of 
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researchers in implementing these devices into practice. In addition, these 
findings can encourage the experimentation with other types of activity monitors 
and compare their strengths and weaknesses to identify a valid but feasible and 
user-friendly device appropriate for DM1 trials. 
 5 
Finally, but most importantly, there is the short-term plan of analyzing the follow-
up data of the full cohort. With the whole sample’s baseline and follow-up data, 
we aim to identify ceiling effect rates for each outcome and establish cut-off 
values that will predict this (and possibly to consider as exclusion criteria in 
clinical trials). The prediction is that very mild participants might not progress 10 
significantly enough to be suitable for effective interventions assessment. For this 
conclusion to be valid a subgroup analysis is required. Moreover, the 
OPTIMISTIC study will reveal whether cognitive behavioural therapy and exercise 
is of benefit to patients with DM1, and the PHENO-DM1 study may reveal blood 
biomarkers suitable to monitor disease progression align with functional changes. 15 
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